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ABSTRACT 
 
 Normal miRNA production is essential for regulating protein expression and cellular fate.  
Misregulation of miRNA production is emerging as a key factor in the development of many 
disease states, including most forms cancer.  A global downregulation of miRNA processing is 
common among cancers and has been shown to drive tumorogenesis.  This global 
downregulation of miRNA biogenesis is caused by the disruption of key enzymes in the miRNA 
biogenesis pathway like Dicer, TAR RNA-binding protein (TRBP) and Drosha.  Herein, the 
enhancement of miRNA processing as a therapeutic strategy is explored.  Developing small 
molecule or peptide based therapeutics that mimic TRBP, an endogenous activator of Dicer, to 
enhance miRNA processing in cancers with reduced miRNA production may lead to safe and 
effective treatments for a number of cancer patients.  Identification of direct activators of Dicer 
will be explored using in vitro kinetic assays with fluorescent probes.   Expression of Dicer, 
TRBP and a peptide-mapping library of TRBP are also described.  Since miRNA biogenesis is 
such a critical pathway in tumorogenesis, activation of this pathway may prove to be an effective 
target in the battle against cancer.  
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1 Introduction 
1.1 miRNA overview 
1.1.1 miRNA biogenesis 
MicroRNAs (miRNAs) are a class of non-coding RNAs capable of regulating the 
expression of target mRNA transcripts.  Successful miRNA production is critical for normal 
cellular function and occurs over multiple steps involving several enzymes.1  miRNAs are 
transcribed by Polymerase II in the nucleus using similar mechanisms to the transcription of 
mRNA.2  In fact, many miRNAs are regulated with the same promoters that control the 
transcription of adjacent genes.  Unlike mRNA transcripts, miRNAs form stem-loop structures 
after transcription due to favorable thermodynamic interactions between nucleotide bases.1  
These stem-loop structures contain imperfect nucleotide pairing in the stem region, and are 
known as primary miRNAs (pri-miRNAs).  pri-miRNAs are recognized by a nuclear RNAse III 
enzyme, Drosha, which cleaves the stem loop structure from the adjacent ssRNA to release a ~70 
nt stem loop structure known as a pre-miRNA. Exportin-5 then transports the pre-miRNA from 
the nucleus to the cytoplasm.  Once the pre-miRNA is in the cytoplasm a second RNAse III 
enzyme, Dicer, recognizes the pre-miRNA and further cleaves it to a mature miRNA (Figure 
1.1).  The mature miRNA is a 20-22 nt dsRNA with 2 nt 3’ overhangs on both ends.  To perform 
the miRNAs ultimate function of regulating target gene expression, one strand of the mature 
miRNA is incorporated into the RNA-induced silencing complex (RISC).  The RISC facilitates 
pairing of the mature miRNA with the target mRNA.  The pairing occurs when the seed region 
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of the miRNA (bases 2-7) is complementary to a sequence on a mRNA strand, at this point 
argonaute 2 (Ago2), the catalytic enzyme in the RISC, degrades the mRNA or facilitates 
repression of translation of the target gene.3,4  
 
Figure 1.1 Schematic of miRNA biogenesis.  pri-miRNA is converted to mature miRNA by 
a number of enzymes including: Drosha, Dicer and TRBP.  
1.1.2 Significance of miRNA pathway 
It is estimated that up to 60% of genes in mammalian cells are regulated by miRNAs.3,5  
This fine tuned regulation of gene expression is a constant and necessary part of healthy cellular 
function.  Perturbations in the biosynthesis of miRNAs affect a cell’s ability to respond to stress.6  
The changes in gene expression caused by perturbations in the miRNA pathway may induce a 
cellular transformation leading to tumorogenicity or cell death.7  There are over 1,000 known 
miRNA in humans, and hundreds of these are highly conserved across a range of mammalian 
species indicating that they play a critical role in normal cellular function.5  Each miRNA may 
regulate the expression of one gene or many hundreds of genes.8  The magnitude of the change in 
expression of the target gene by miRNAs is generally smaller than the effect observed by 
transcription factors, but their combined influence is significant as they regulate the expression 
of so many genes across all cellular pathways.8  This fine tuning by miRNAs is essential for 
controlling cellular fate and identity.   
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1.2 Misregulation of miRNA processing and disease 
Since the production of miRNA is so critical to normal cellular function, it is not 
surprising that misregulation of this pathway can lead to cellular transformation and 
tumorogensis.  In 2005, Lu et al. reported a global down regulation of miRNA levels in cancer.9  
This phenomenon was observed in all cancers tested including colon, kidney, prostate, uterus, 
lung and breast (Figure 1.2).  At first, the source of this downregulation was unclear. One clue to 
its source was that it affected nearly all miRNAs rather than just a few specific miRNAs.  The 
global nature of the downregulation of miRNA production suggests that changes in the core 
miRNA maturation enzymes rather than transcriptional changes of individual miRNAs were 
responsible.   
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Figure 1.2 Downregulation of miRNA processing in tumors.  miRNA levels were assessed in 
32 normal tissues and 43 tumor tissues from the six indicated organs.  Red=increased 
miRNA levels; Blue=decreased miRNA levels.  Figure adapted from Lu et al.9 Used with 
permission from Nature Publishing Group. 
Soon after the observation of a global downregulation in miRNA processing, studies 
showed that a large percentage of tumors have decreased expression levels of the key RNAse 
enzymes Dicer and Drosha at both the RNA and protein level.10,11  Not only did a significant 
fraction of these tumors have downregulated expression of Dicer and Drosha; but also, patients 
with tumors containing reduced Dicer and Drosha expression had a much poorer prognosis than 
those with normal or high levels (Figure 1.3).11  While Dicer and Drosha levels both had an 
impact on prognosis, the effect was more pronounced with Dicer.  This downregulation of Dicer 
occurs frequently in cancer and it has been reported in many different cancer types, including 
breast,10 ovarian,11,12 lung,13 CLL,14 bladder,15 nasopharyngeal,16 endometrial,17 neuroblastoma,18 
liver,19 and gallbladder adenocarcinoma.20 
 5 
 
Figure 1.3 Decreased Dicer expression results in poor prognosis.  Kaplan-Meier survival 
curves for patients with low or high mRNA levels of Dicer in ovarian, lung and breast 
cancer.  Figured adapted from Merritt et al.11 Used with permission from N Engl J Med 
2008, 359, 2641-50. Copyright Massachussets Medical Society. 
1.2.1 Regulation of cellular levels of Dicer 
There are many different potential sources of decreased Dicer expression.  One common 
source is chromosomal deletion.  Kumar et al. showed that Dicer is a haploinsufficient tumor 
suppressor.21   If one allele of Dicer is lost, this results in increased tumorogensis due to 
decreased production of mature miRNAs.  If both copies of Dicer are lost, the cell is not viable 
and no tumor growth occurs. By analyzing data from the cancer genome atlas, Kumar et al. 
demonstrated the frequency of hemizygous deletion of Dicer in a number of cancer types (Table 
1.1).21  It is important to note that the high frequency of hemizygous deletion is not due to 
instability of that region of the genome, since no copy number amplifications were observed and 
also no homozygous deletions were observed.  Lambretz et al. also confirmed this 
haploinsufficient tumor suppressor effect of Dicer.22  Knocking out both copies of Dicer is 
embryonic lethal, thus giving further credence to the argument that Dicer and miRNAs play a 
central and critical role in normal cellular development and homeostasis.23  In addition to 
hemizygous deletion of Dicer, other chromosomal changes of Dicer have been shown to induce 
cancer.  Recently, germline mutations in Dicer have been shown to induce familial 
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pleuropulmonary blastoma,24 which further demonstrates Dicer’s critical role as a tumor 
suppressor.   
Tumor Type Fraction of tumors with Dicer hemizygous loss 
Breast 17/45 
Kidney 13/21 
Large Intestine 14/39 
Liver 3/9 
Lung 37/149 
Ovary 6/22 
Pancreas 6/16 
Stomach 9/21 
Table 1.1 Frequency of hemizygous loss of Dicer according to the cancer genome atlas.21 
Other studies have shown expression levels of Dicer are also regulated by transcription 
factors.  Dicer contains multiple target sequences for E2F transcription factors in its promoter 
that have been shown to regulate the transcription of Dicer.25   Additionally, in melanocytes 
expression of Dicer is driven by the lineage specific transcription factor, MITF.26  Not only are 
Dicer levels affected by chromosomal changes and transcription factors, but Dicer translation is 
regulated by miRNAs. Some of the key miRNA regulators of Dicer are the Let-7 family of 
miRNAs27 as well as the miR 103/107 family.28  Protein levels of Dicer are also known to be 
regulated post-translationally.  TRBP has been shown to be a key regulator of intracellular Dicer 
levels.29  TRBP enhances Dicer’s stability and therefore increases its cellular concentration.  
Mutations negatively affecting the expression or stability of Dicer in any of these pathways 
(chromosomal deletions, chromosomal mutations, transcription factor signaling, miRNA 
regulation and post-translational stability) have resulted in a transformed phenotype. 
1.2.2 Defective miRNA processing drives tumorogenesis 
Many cancers contain cellular changes that do not drive tumorogenesis but rather are a 
phenotype of the transformed cellular state.30  To address this issue, Kumar et al in 2007 showed 
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both in vitro and in vivo that decreased expression of Dicer drove tumorogenesis.31  These cells 
showed greater tumorogenicity and global downregulation of miRNA processing as is observed 
frequently in tumors.  One of the hallmarks of cells with decreased miRNA production is that the 
cells are no longer able to maintain their differentiated state and revert to a more stem-cell like 
state with increased replicative and metastatic potential.32  Perhaps the most well characterized 
example of this transformation is the epithelial to mesenchymal transformation in breast cancer 
tissue containing low levels of mature miRNA.33,34  These mesenchymal cancers are more 
aggressive and result in a poorer prognosis due to their increased metastatic potential.33 
1.2.3 Dicer’s involvement in DNA repair and implications for tumorogenesis 
In addition to Dicer’s tumor suppressive role as a key enzyme in the production of 
miRNAs, Dicer has been implicated with another important cellular process: DNA repair (Figure 
1.4).35  Upon ionizing radiation of cells, dsDNA breaks are formed throughout the genome.  The 
cell responds to these dsDNA breaks by activating the kinase activity of the ataxia-telangiectasia 
mutated gene (ATM), which initiates a signaling cascade resulting in the recruitment of DNA 
damage response enzymes to the site of the lesion.  These DNA damage response enzymes halt 
cell cycle progression and repair the damaged DNA to ensure genome integrity of the daughter 
cells.  Recently, it was demonstrated that this DNA damage response is RNA dependent and that 
non coding RNAs (ncRNAs) act as a scaffold for these DNA damage response enzymes to help 
localize them to the site of damage, without the RNA, there is no localization of these enzymes 
to the lesion and therefore no DNA repair.36   
The production of functional ncRNA, that can act as a scaffold for repair enzymes, 
utilizes many of the same enzymes that are involved in miRNA production.  In response to the 
lesion, RNA is transcribed from the adjacent DNA and these ncRNAs are processed by both 
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Drosha and Dicer to generate 20-25 nt fragments.  These RNAs are referred to as DNA Damage 
RNAs (DDRNAs).  These DDRNAs are not used to affect gene expression as is seen with 
miRNAs, rather they serve as scaffolds for DNA repair enzymes at the site of the lesion.  This 
recently discovered function for Dicer might play an important role in cancer.  Mutations in 
DNA repair enzymes are frequently the driving force in tumorogensis, as these cells are rapidly 
able to acquire additional mutations rendering the cells increasingly more aggressive.37  This 
means that both Drosha and Dicer function in a DNA repair pathway, which may add to their 
tumor suppressor roles beyond the regulation of miRNAs.  When Dicer or Drosha levels are 
reduced, there is reduced production of DDRNAs leading to any inability to signal for cell cycle 
arrest and DNA lesion repair.36  Propagation of these errors result in genomic rearrangements 
and copy number variations that are frequently hallmarks of cancer genomes.  More research 
must be performed to understand if the down regulation of Dicer causes cancer through a 
downregulation of miRNA production, DDRNA production or a combination of both pathways.  
Regardless of the pathway, therapeutics that activate and/or stabilize Dicer are expected to 
promote its tumor suppressive functions. 
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Figure 1.4 Overlapping roles of key miRNA enzymes.  Top) Schematic of miRNA 
biogenesis.  Bottom) Schematic of RNA mediated dsDNA break repair. 
1.2.4 Identification of mutations in TRBP 
Since the core RNA production machinery is so critical to normal cellular function, it seems 
likely that misregulation of any of the other enzymes besides Dicer and Drosha may result in a 
transformed phenotype.  Melo et al. in 2009 sequenced all of the major genes involved in 
miRNA processing (Drosha, DGCR8, exportin 5 (XPO5), Dicer1, Ago2 and Tarbp2) in 
heteronuclear non-polyposis colorectal carcinoma (HNPCC) cells containing microsatellite 
instability (MSI+).  These cells are known to frequently harbor mutations in their mismatch 
repair enzymes MSH2 and MLH1.38  They found evidence for mutations in both TRBP and 
Xpo5.  26% of these HNPCC colon cancer cells contained a frameshift mutation in exon 5 of the 
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gene tarbp239, and 22% contained an inactivating mutation in Xpo5.40 Both of these mutations 
result in premature truncation that disrupts miRNA biogenesis. 
1.2.5 Functional TRBP is required for normal cellular function 
HNPCC cells lacking functional TRBP demonstrate a decreased ability to produce 
mature miRNAs.  This decreased miRNA production leads to increased tumorogenicity as 
measured in both colony formation assays in soft agar as well as xenograft cancer models in 
mice.39  Stable transfection of WT TRBP into these HNPCC cells resulted in increased miRNA 
production and reduced tumorogeneticity as measured by colony formation and xenograft growth 
in mice.  Stable transfection of mutant TRBP containing the frameshift mutation of TRBP was 
unable to restore miRNA production or reduce tumor growth (Figure 1.5).  This data 
demonstrates that functional TRBP is critical for normal cellular function and that loss of TRBP 
reduces miRNA production and drives tumorogenesis.  In addition to these studies, other studies 
have demonstrated that TRBP has a dual function of enhancing Dicer’s catalytic efficiency as 
well as stabilizing Dicer protein levels.41,42   Learning more about the interaction between Dicer 
and TRBP may lead to knowledge that enables the design of small molecules or peptides that 
mimic TRBPs ability to enhance Dicer’s activity in cancers with decreased miRNA or DDRNA 
production. 
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Figure 1.5 TRBP reduces tumorogenesis.  A & B) Transfection of WT TRBP into HNPCC 
cells (Co115) containing a mutation in TRBP reduces colony formation in soft agarose and 
reduces tumor growth in mouse xenografts.  C & D) Transfection of mutant TRBP is 
unable to reduce colony formation in soft agarose and unable to reduce tumor growth in 
mouse xenografts.  Adapted from Melo et al.39 Used with permission from Nature 
Publishing Group. 
1.2.6 Situations where increased miRNA processing may be harmful 
There are, however, a few examples in the literature of increased Dicer being correlated 
with poor prognosis and miRNAs that are oncogenic.  The most well studied of such cases is the 
oncongenic mir-17-92, which is commonly found in ALL, AML, and hepatocellular 
carcinoma.42,43   When mir-17-92, containing six polycistronic miRNAs, is amplified through 
chromosomal duplications it acts to decrease expression of important tumor suppressor genes.  In 
a situation where tumor growth is driven by chromosomal duplications in mir-17-92, one would 
predict that enhancing the miRNA processing could be detrimental, as it would result in 
increased production of these oncogenic miRNAs and decreased expression of their target tumor 
suppressors.  There are additional examples of cancers where increased expression of Dicer is 
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associated with poor prognosis.  These cancers include colorectal carcinoma,44 soft-tissue 
sarcoma,43,45 cutaneous melanoma,45 oral cancer,46 and prostate adenocarcinoma.47  It is unclear 
in these cancers whether increased Dicer expression is driving the tumorogenesis or whether it is 
upregulated in response to DNA damage or viral infection. Therefore, while enhancing miRNA 
processing may not be ideal for every cancer, a treatment that could enhance miRNA processing 
would be widely applicable to treat a large percentage of cancers observed in the clinic. 
1.2.7 Dicer and age-related macular degeneration 
Another potential clinical use for activators of Dicer is in patients with age-related 
macular degeneration, the leading cause of vision loss.  A recently published paper established 
that Alu repeats, which are ubiquitous throughout the genome, are transcribed and these 
transcribed RNAs are toxic to the retinal pigment epithelium.48  In healthy cells containing 
normal levels of Dicer, these Alu repeats are cleaved by Dicer into short fragments rendering 
them non-toxic.  Decreased expression or activity of Dicer facilitates the accumulation of toxic 
Alu repeat RNAs leading to destruction of retinal pigment epithelial cells.  Enhancing Dicer’s 
activity is an attractive therapeutic strategy to explore in this disease.  Targeting an ocular 
disease may circumvent many of the pitfalls associated with biodistribution and 
pharmacodynamics that often challenge cancer drugs as they pass through the blood stream on 
their way to their intended target.  Ocular therapies can be applied directly to the site of disease 
allowing for an increased repertoire of therapeutic approaches to be explored. 
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1.3 Structural and biochemical analysis of Dicer and associated proteins 
1.3.1 Structure of Dicer 
To develop a therapeutic capable of activating Dicer, it helps to understand how Dicer 
functions and how TRBP, the endogenous activator of Dicer, interacts with Dicer.  Many of 
these structural and biochemical details remain elusive, but much progress has been made during 
recent years in increasing our understanding of these enzymes.  Dicer is a large (219 kDa) 
protein containing six functional domains (Paz, RNAse III (a), RNAseIII (b), dsRBD, DUF283, 
and Helicase).  High-resolution structural information on human Dicer is lacking because no 
crystal structures have been reported.  In 2006, Jennifer Doudna and coworkers reported the 
crystal structure of Dicer from the simple eukaryote Giardia.49  Dicer from Giardia has many 
features in common with human Dicer including the Paz domain, 2 RNAse III domains and a 
dsRBD, however it lacks the helicase domain.  The crystal structure revealed that the Paz domain 
binds to the 2-nt 3’ overhang of the pre-miRNA and positions the pre-miRNA such that the two 
RNAse III domains cleave the dsRNA into 24 nt products.  This crystal structure accelerated our 
structural and functional understanding of Dicer’s role in miRNA biogenesis. 
1.3.2 Dicer’s helicase domain 
Additional reports of Dicer’s structure have come forth, but one domain in particular, the 
helicase, has remained enigmatic. While most helicases require ATP hydrolysis to unwind target 
nucleotide strands, The ATPase activity of Dicer’s helicase is non-essential and dicing proceeds 
without the addition of ATP.  Additional studies show that when the helicase domain contains a 
Walker mutation, eliminating ATP hydrolysis, there is no effect on the rate of dicing. What is the 
function then of the helicase domain if it is not behaving as a typical helicase?50  MacRae and 
coworkers have generated a low-resolution L-shaped structure of human Dicer using 3D 
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reconstruction techniques from electron microscopy images.51  Further studies in their lab helped 
define the domain architecture of Dicer and to localize the helicase domain in the 3D 
reconstruction space.52  The helicase domain forms a large clamp shape at the base of the 3D 
reconstruction space opposite the PAZ domain.  This clamp circumscribes the RNA and is 
thought to play a key regulatory role in Dicing activity.  In fact, Ma et al. expressed human Dicer 
lacking the helicase domain and showed that it had 40 fold increased rate of dicing, they 
proposed that the helicase domain is autoinhibitory.53 
1.3.3 Comparison of Dicer’s helicase domain to RIG-I 
Since there is no high-resolution crystal structure for the helicase domain of Dicer, one 
must learn from its closest evolutionary relative, retinoic acid-inducible gene I (RIG-I). RIG-I is 
a helicase involved in viral response. Four groups simultaneously solved the crystal structure of 
RIG-I in 2011.54-57 RIG-I has a dynamic structure and each group crystallized the structure in 
slightly different conformations.  By compiling the information from the available structures, the 
dynamics of RIG-I come to life.  The most obvious dynamic is that when RIG-I binds to dsRNA 
there is a large conformational change as the protein clamps around the dsRNA forming many 
favorable contacts.  The other structural component of RIG-I that is relevant to Dicer’s function 
is the HEL2i domain, which contains a bundle of five α-helices that extend out from the HEL2 
domain.  When RNA is absent, the HEL2i domain serves as an important docking station for the 
caspase activation and recruitment domains (CARDs).  When RIG-I is bound to viral RNA, the 
C-terminal domain (CTD) displaces the CARDs and binds to an overlapping region of the HEL2i 
domain such that the CARDs and the CTD cannot both simultaneously dock to the HEL2i 
domain.  Therefore, the HEL2i domain acts as an important docking station that controls 
recruitment of cofactors that regulate the function and signaling of RIG-I.  This HEL2i domain 
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on RIG-I is important because homology modeling of RIG-I with the helicase domain of Dicer 
shows that the domain to which TRBP binds (267-431) is positioned between HEL1 and HEL2 
just like the HEL2i domain in RIG-I (Figure 1.6).58  This suggests that this region of Dicer (267-
431) may serve as a regulatory role similar to that of the HEL2i domain in recruiting co-factors 
to assist with modulating Dicer’s activity or stability.  TRBP is known to increase Dicer’s 
stability, and it is possible that it behaves in a similar manner as the CTD on RIG-I.   
 
Figure 1.6 Sequence homology between RIG-I and the helicase domain of Dicer.  Note the 
similar location of the TRBP binding domain as the HEL2i domain of RIG-I. 
Dicer’s (267-431) domain is unique and there are no known proteins that share sequence 
similarity with this domain.  The 69 amino acid domain of TRBP is also unique, only one other 
protein, protein activator of interferon-induced protein kinase (PACT), shares sequence 
homology with this domain; it is not surprising that PACT also binds to Dicer.37  It is possible 
that regulation of these two proteins and their interaction with Dicer controls Dicer activity, 
stability or function.  TRBP and PACT are known to be able to form homodimers and 
heterodimers and they form these dimers through the same C-terminal domain that interacts with 
Dicer.59   There is a clear need to improve our understanding of the interaction between Dicer 
and these two crucial regulators.  This protein-protein interaction is an attractive target of further 
study since it is a novel and entirely unique to Dicer, TRBP and PACT. 
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1.3.4 TRBP structure 
Like Dicer, the structure of TRBP is also not fully characterized.  TRBP is a much 
smaller protein (43 kDa) with three domains connected by flexible linkers; its flexibility has 
made it difficult to crystallize (Figure 1.7).  Originally all three domains were classified as 
double-stranded RNA binding domains (dsRBDs).  Further studies have shown, however, that 
the third dsRBD is incapable of binding to RNA and that this is the region that interacts with the 
helicase domain of Dicer.58  Yeast two hybrid studies have narrowed this down to the 69 amino 
acids at the C-terminus of TRBP (298-366).58,60  While the structures of the first two dsRBD 
have been solved by x-ray crystallography,61 this third, C-terminal domain’s structure remains to 
be solved.   
 
Figure 1.7 Structure of TRBP.  TRBP contains two dsRBDs and a C-terminal domain that 
is involved with its interaction with Dicer. 
When TRBP associates with Dicer, there is a significant rate enhancement in dicing 
activity.  TRBP acts to relieve some of the autoinhibitory effect of the helicase domain.62  
Therefore, TRBP not only stabilizes Dicer protein levels, but increases its ability to process pre-
miRNA (Figure 1.8).  This two-fold effect makes TRBP a key regulator of Dicer.  Further 
characterization of this novel domain of TRBP that interacts with the helicase domain of Dicer 
would greatly assist in advancing our understanding of miRNA biogenesis. 
 17 
 
Figure 1.8 TRBP enhances miRNA processing.  A) TRBP and a phospho-mimic of TRBP 
increase Dicer’s ability to cleave a pre-miRNA to a mature miRNA in vitro.  B) 
Transfection of WT TRBP into HNPCC cells lacking functional TRBP causes a 3.5 fold 
increase in mature miRNA levels in vivo.  Figures adapted from Chakravarthy et al.62 and 
Melo et al.39 Used with permission from the Journal of Molecular Biology and Nature 
Publishing Group. 
1.4 miRNA enhancement as a therapeutic target 
1.4.1 Selectivity of a Dicer activating therapeutic strategy to cancer cells 
This strategy is a personalized medicine strategy and the status of miRNA processing 
would need to be assessed to ensure that the right patients are receiving the right treatments.  In 
healthy cells upregulation of dicing activity is predicted to have little to no effect because the 
energy dependent export of the pre-miRNAs is rate limiting, and once the pre-miRNA is in the 
cytosol, it is immediately processed by Dicer and TRBP to produce mature miRNA.  This 
treatment strategy should therefore be selective to cancer cells with a downregulation in dicing 
activity by restoring dicing activity in these cells to normal levels. 
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1.4.2 Literature reports of small-molecule activators of miRNA processing 
Since we began this project, two small molecules have been reported to enhance miRNA 
processing in cancer cells.63,64  These compounds, enoxacin and metformin, are already approved 
for the treatment of other non cancer related diseases.  Enoxacin, a fluoroquinolone, is used as an 
antibiotic for the treatment of urinary tract infections and metformin, a biguanide, is a first-line 
drug of choice for the treatment of type II diabetes.   
These compounds have distinct modes of action.  Melo et al. demonstrated that enoxacin 
binds to TRBP and in some way, not fully explained, this binding event helps to enhance Dicer’s 
ability to process miRNA.63  They demonstrated that in the absence of TRBP, enoxacin is no 
longer capable of enhancing miRNA processing.  Since it is unclear how TRBP activates Dicer, 
it is even less clear how enoxacin binding to TRBP helps to activate Dicer. Treatment with 
enoxacin results in tumor reduction in mice and a normalization of miRNA processing.63  This 
study clearly demonstrates that activation of the miRNA pathway is safe and effective and lends 
further credence to activation of Dicer as a therapeutic target. 
Epidemiological studies of diabetes patients taking metformin have shown that these 
patients have a reduced incidence of cancer.65-67  Blandino et al. analyzed the effect of  
metformin on miRNA processing and how this may relate to cancer.25  A clear mechanism of 
how metformin restores miRNA processing is presented.  Metformin enhances the signaling of 
the E2F transcription factor pathway.  Three E2F transcription factors regulate Dicer’s 
expression, two of them, E2F1 and E2F3, positively regulate Dicer expression, while the third, 
E2F5, is a negative regulator.  Metformin increases E2F3 signaling and decreases E2F5 
signaling, which combine to cause increased Dicer expression.  This increased Dicer expression 
causes increased production of mature miRNAs and a down regulation of key oncogenes, Myc, 
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Hif1 and IRS1.  They also demonstrate that these cells with increased miRNA processing have 
reduced tumorogenic potential.  Especially impressive was metformin’s ability to prevent tumor 
implantation and to completely transform the metabolic energy profile of the cancer to that of a 
normal cell.   
Both of these compounds validate activation of the miRNA pathway as a safe and 
effective cancer treatment.  These medications have been prescribed for years and they maintain 
a favorable toxicity profile.  While these medications are already FDA approved and have 
demonstrated great efficacy in tumor models, it is still to be seen how effective they are in 
clinical trials with cancer patients. 
1.4.3 Key advantages of direct activation of Dicer 
These compounds do not, however, directly activate Dicer.  For example enoxacin relies 
on functional TRBP.  In colon cancer with mutant TRBP, enoxacin is ineffective in restoring 
miRNA processing.39  For metformin, there are many enzymes upstream of Dicer transactivation 
and mutations in these enzymes may render this pathway ineffective to metformin treatment.  
Direct activation of Dicer is particularly relevant in the subset of HNPCC patients with MSI+ 
who lack functional TRBP.  Replacing the function of the missing endogenous activator, TRBP, 
will provide a crucial tumor-suppressive function and result in reduced tumor growth and 
increased survival.  Herein is described a methodology to learn from the endogenous activator of 
Dicer, TRBP, and design a small molecule or peptide that is capable of directly activating and or 
stabilizing Dicer.  This will directly lead to increased miRNA production even in the presence of 
mutations in TRBP or in the E2F transcription factor pathway. 
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2 Progress towards direct activation of Dicer 
2.1 Project design 
Endogenous activation of Dicer has been demonstrated with TRBP.  Learning from this 
interaction between TRBP and the helicase domain of Dicer may assist in the development of 
novel therapeutics that mimic this interaction.  After further characterization of this novel 
interaction, design and development of a small molecule or a peptide capable of directly 
activating Dicer will be pursued.  This direct activation of Dicer will allow for enhanced miRNA 
production even in the presence of upstream mutations that may render other treatments 
ineffective.  Restoration of miRNA processing is emerging as a safe and effective treatment for 
cancer as many cancers have a downregulation of miRNA activity. 
To design or identify an activator of Dicer, three essential components are required in an 
in vitro Dicer activation assay: 1) Dicer, 2) RNA probe and 3) an activator (Figure 2.1).  Dicer 
will be expressed and purified recombinantly from SF9 insect cells.  The RNA probe should 
utilize a fluorescent readout making it amenable to plate-based screening that is scalable to a 
high-throughput process; additionally, the assay should be a continuous kinetic assay to easily 
identify changes in dicing rates.  The third and final ingredient for designing or identifying an 
activator of Dicer is the activator itself.   Three different approaches will be used to activate 
Dicer; these include expression of full length human TRBP as a positive control, the generation 
of a peptide library spanning the domain of TRBP known to interact with Dicer to determine if 
any of these peptides are capable of binding to and activating Dicer by a similar magnitude as 
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full length TRBP, and the third type of activator is a small molecule, to identify such a small 
molecule, a high-throughput screen will be employed. 
 
Figure 2.1 Project design: Dicer (1), RNA probe (2), and activator (3).  A) TRBP will be 
tested for its ability to enhance dicing of a RNA probe.  B) A TRBP peptide-mapping 
library will be tested for its ability to enhance dicing.  C) A library of small molecules will 
be tested for their ability to enhance dicing.  
2.2 Expression and purification of Dicer 
2.2.1 Production of recombinant bacmids 
In order to design an in vitro experiment to assess Dicer’s activity, expression of 
recombinant Dicer was needed.  A few groups have reported the expression of Dicer,68 but the 
most compelling perhaps is the procedure developed by Ian McRae and co-workers.69  Three 
pFastBac constructs were received from Jennifer Doudna: full-length human Dicer (hDcr), Dicer 
lacking the helicase domain (∆Helicase), and full length Dicer containing a mutation in the 
helicase domain (hWalker).  The process of expressing these proteins began by preparing 
chemically competent DH10Bac E. coli from Invitrogen and transforming the pFastBac plasmids 
into these cells.  After a four hour incubation to allow for recombination, the cells were plated 
onto Luria Broth (LB) agar containing antibiotics, Blue-gal, and IPTG.  When recombination 
into the bacmid occurs successfully, the LacZ gene is disrupted and thus no β-galactosidase is 
expressed so that colonies appear white.  Ten white colonies were selected from each construct 
 22 
and restreaked onto LB agar plates containing antibiotics, IPTG, and Bluo-gal.  Once each 
colony was confirmed to be a true white colony, overnight cultures were prepared and the 
bacmid DNA was isolated using a modified plasmid DNA isolation technique capable of 
isolating high-quality bacmid DNA.  Using this procedure, bacmid DNA was obtained at a 
concentration of 1-2 mg/ml.  Correct insertion of each Dicer construct was confirmed by PCR 
amplification using the M13 forward and M13 reverse primers.  Due to the high GC content and 
long length of the inserts, a high fidelity polymerase such as PfuUltra was required for successful 
PCR amplification.  The length of the insert was measured by agarose gel electrophoresis and the 
correct length of the insert was confirmed (PCR product = 2440 bp + length of gene insert). 
2.2.2 Production of recombinant baculovivrus through transfection and amplification 
The recombinant DNA was transfected into SF9 insect cells in 6-well plates using 
Cellfectin II from Invitrogen.  After seven days of incubation at 27 °C in a humidified 
environment, the media, containing the recombinant baculovirus, was harvested; this initial 
baculoviral stock is known as passage 1 (P1).  The P1 baculovirus was amplified by infecting 
either adherent SF9 cells in T-75 flasks or suspension SF9 cells in an 1L spinner flask.  The cells 
were infected at a multiplicity of infection (MOI) of 0.05 – 0.1 with the P1 viral stock.  The viral 
stock was amplified effectively a couple of times, up to P3, however, the P4 baculovirus was no 
longer effective due to an accumulation of defective interfering particles (DIPs).  The viral titer 
of the amplified baculoviral stock was determined using a plate-based plaque assay on media 
containing low-melting point agarose.  After thirteen days, plaques were visualized by staining 
with Neutral Red and the viral titer was determined to be 1x108 pfu/ml for both P2 and P3 
amplified baculoviral stocks. 
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2.2.3 Expression and purification of Dicer in adherent SF9 cells 
Once high quality, amplified baculoviral stocks were produced, pilot expression studies 
of Dicer in adherent cells began.  Exponentially dividing (70-80% confluency) SF9 cells in T-75 
flasks were infected with 1 mL of P2 or P3 baculovirus (MOI: 10).   The cells were harvested 
after four days and lysed using detergent and a Dounce grinder in the presence of protease 
inhibitors.  Dicer was purified from the cleared lysate using a small amount of Ni-NTA affinity 
resin.  The protein was electrophoresed on SDS-PAGE gel and stained with Coomassie Blue 
(Figure 2.2 left panel).  Additionally, the protein was transferred to a PVDF membrane and 
visualized with an α-Dicer mouse monoclonal antibody (13D6 from Abcam) (Figure 2.2 right 
panel). 
 
Figure 2.2 Heterologous expression and purification of human Dicer from adherent SF9 
cells. Left) Coomassie stain of fractions from Ni-NTA purification of Dicer.  Right) α-Dicer 
Western Blot of fractions from Ni-NTA purification of Dicer.  FT=flow-through, W1-
W3=Washes 1-3, E1 and E2=Elutions 1 and 2. 
2.2.4 Expression and purification of Dicer in suspension SF9 cells 
After expression of full-length human Dicer on a small scale in adherent SF9 insect cell 
culture, the process was scaled up to produce larger quantities of Dicer for use in screening.  25 
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mL of P2 or P3 hDcr baculovirus was added to 600 mL of exponentially dividing cells (2.0x106 
cells/mL) in a 1L spinner flask.  50 mL of cells were harvested every 24 hours over a four-day 
period to determine the optimal timing for Dicer expression.  The cells were pelleted and stored 
at -20° C.  After collection of all of the cell pellets at the four time points (24, 48, 72, and 96 
hours) the cells were lysed and Dicer was purified by Ni-NTA affinity chromatography.  The 
proteins were analyzed by SDS-PAGE and stained with Coomassie Blue and visualized by 
Western Blot (Figure 2.3).  An increase in expression of Dicer was observed up to 72 hours, 
following which there was a significant decrease in yield due to cell lysis and proteolytic 
degradation.  Since the optimal time-course of Dicer expression was determined to be around 72 
hours, all subsequent SF9 cells from expressions in SF9 suspension cell culture were harvested 
between 66 and 72 hours to ensure the highest possible yields. 
 
Figure 2.3 Time course of Dicer Expression.  Left) Coomassie stain of Ni-NTA purified 
Dicer at indicated time points.  Right) α-Dicer Western Blot of Ni-NTA purified Dicer at 
indicated time points. 
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This Dicer from a 72 hour expression and subsequent Ni-NTA affinity purification is 
fully capable of dicing dsRNA substrates; however, it is difficult to quantify the amount of Dicer 
present due to the abundance of other contaminating proteins (Figure 2.3).  To obtain more 
precise rate constants and to rule out any possible confounding variables from contaminating 
proteins, Dicer must be further purified.  It is important to note, however, that the mock-
transfected (Dicer-free) SF9 cells that followed identical Ni-NTA purification procedure showed 
no dicing activity (Figure 2.10).  Therefore, it would be possible to screen for small-molecule or 
peptide-based activators of Dicer even at this stage of purification since the dicing activity 
observed in the assay is exclusively from Dicer and not other contaminants. 
2.2.5 TEV cleavage and reverse Ni-NTA purification 
When using SF9 insect cells, many endogenous proteins bind to Ni-NTA resin during 
purification; therefore, it is difficult to obtain pure recombinant protein with one step.  For this 
reason, the pFastBacs containing Dicer have an engineered TEV protease site between Dicer and 
the His6 affinity tag to aid with purification. After an initial purification of Dicer containing a 
His6 affinity tag, the tag is removed and the protein is resubjected to Ni-NTA affinity 
purification, but is eluted with the flow-through while the contaminating proteins bind to the 
resin.  TEV protease was expressed and purified in house and Ni-NTA purified Dicer was treated 
with TEV protease overnight.70  Following cleavage of the His6 affinity tag, the protein was run 
back over Ni-NTA resin and Dicer should have eluted in the flow-through while the 
contaminating proteins would be retained on the resin and eluted with a higher concentration of 
imidazole.  Despite multiple attempts at this procedure using different columns, different buffers, 
switching between batch loading and direct addition, Dicer never eluded in the flow-through, 
washes, or elution (Figure 2.4).  The source of Dicer loss remains unknown, however, some 
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possibilities for this include:  attachment to the Ni-NTA resin, insolubility, precipitation or 
attachment to the plastic/glass surfaces of the column.  If Dicer had eluted in the flow-through or 
washes, this method would result in high purity protein since the contaminating proteins do in 
fact bind to the Ni-NTA resin and are only eluted later with a high concentration of imidazole 
(Figure 2.4). 
 
Figure 2.4 Analysis of TEV cleavage and reverse Ni-NTA purification of Dicer.  Left) 
SyproRuby staining of fractions before TEV cleavage, after TEV cleavage, and subsequent 
reverse NI-NTA purification.  Right) α-Dicer Western blot of fractions before TEV 
cleavage, after TEV cleavage, and subsequent reverse NI-NTA purification. 
2.2.6 Size exclusion purification of Dicer 
Since the reverse Ni-NTA purification was unsuccessful, size exclusion chromatography 
was used and significantly enhanced the purity of Dicer relative to the levels obtained with Ni-
NTA purification alone.  Interestingly, the contaminating proteins form a large multi-protein 
complex that is stable to the conditions of size exclusion chromatography rather than behaving as 
discrete proteins.  This stable multi-protein complex has a larger Stokes radius than Dicer and 
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elutes first from the column (Figure 2.5).  There is partial overlap between the elution of these 
contaminating proteins and Dicer, and for this reason, Dicer could only be purified to 
approximately 20-25% purity as determined by densitometry measurements of SYPRO Ruby 
stained SDS-PAGE gels (Figure 2.5). 
 
Figure 2.5 Analysis of size exclusion purification of Dicer.  A) UV trace (280 nm) of size 
exclusion purification of Dicer.  B) SyproRuby analysis of fractions from size exclusion 
purification of Dicer.  C) Densitometry to estimate purity of Dicer in the three indicated 
fractions. 
2.2.7 Challenges associated with Dicer purification 
Dicer remains a challenging protein to purify due to its low expression, poor long-term 
stability and its ability to readily bind to surfaces, including cellulose, glass and all forms of 
plastic.  Dicer could not be concentrated by centrifugation using concentrating tubes, because it 
nearly completely binds to the cellulose membrane resulting in significant protein loss.  An 
alternate procedure using dialysis membranes, and poly(ethylene glycol) 8500 (PEG 8500) was 
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devised for when concentration of Dicer was required.  Additionally, Dicer’s high affinity for 
attachment to cellulose precluded the use of syringe filters to remove debris. 
2.2.8 Increased expression and purity of Dicer 
A large portion of the difficulty in the purification process of Dicer may be partially 
remedied by increasing the expression of Dicer.  To test if higher expression levels of Dicer 
could be obtained, 25 mL of P2 Dicer baculovirus was sent to the University of Colorado Protein 
Production facility.  Using their SF9 cells and their equipment, 25 mL of baculovirus was added 
to 500 mL of SF9 cells (2x106 cells/mL).  After 72 hours, the cells were harvested.  Dicer was 
purified following the same procedure used for the protein expressed in-house.  A significant 
increase in expression of Dicer was observed for the protein expressed in their system despite 
using half the quantity of cells (167 mL pellet vs. 300 mL pellet) (Figure 2.6).  Some possible 
reasons for the discrepancy in the results include:  1) Different media conditions (Grace’s media 
vs. ESF-921) 2) Differences between lots of fetal bovine serum (FBS) 3) Differences in growth 
conditions (heat from stir plate, impeller speed, and oxygenation of cells).  Future studies may be 
beneficial to optimize conditions for Dicer expression.  The valuable services of the University 
of Colorado Protein Production facility enabled the purification of Dicer to >60% purity whereas 
before only 20-25% was obtainable. 
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Figure 2.6 Analysis of improved purification of Dicer on size exclusion chromatography.  
A) UV trace (280 nm) of size exclusion purification of Dicer.  B) SyproRuby analysis of 
fractions from size exclusion purification of Dicer.  C) Densitometry to estimate purity of 
Dicer in the three indicated fractions. 
2.3 Fluorescent RNA-based assay development 
2.3.1 Previous methods of detecting dicing activity 
At the commencement of this research project, no reliable assays had been developed to 
directly measure dicing activity in a continuous kinetic-based assay.  The few assays that had 
been used for determining rate constants relied on discrete time points and the methods were not 
amenable to a high-throughput screening effort.  The gold standard for measuring dicing activity 
is a radiometric gel shift assay using P32 labeled pre-miRNA.53  After coincubation of Dicer and 
the pre-miRNA for various time periods, the cleaved mature miRNA is separated from the 
uncleaved pre-miRNA by denaturing urea electrophoresis and visualized.  The fraction of pre-
miRNA cleaved at the various time points dictates the determined rate constants for Dicer.  This 
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method is sensitive and reliable since the substrate can be nearly identical to the native pre-
miRNAs being studied.  Another method of detecting small molecules capable of enhancing the 
miRNA pathway is to use a cell-based GFP reporter assay.  This method is amenable to high 
throughput screening and has the advantage that any molecule identified that enhances miRNA 
production is already known to be active in a cellular environment.  This is the method by which 
enoxacin was initially identified as a modulator of miRNA biogenesis.64  The major disadvantage 
of this strategy, however, is that it is not specific for Dicer, meaning the drug target can be any 
number of proteins up or downstream of Dicer.  Once a molecule is identified through such a 
pathway, it remains a challenge to identify its target and mode of action. 
Development of a cost-effective strategy to measure dicing activity that is both amenable 
to high-throughput screening and could be used to collect continuous kinetic data as opposed to 
discrete endpoint reads would greatly assist in the identification of a direct activator of Dicer.  
Working towards this goal, two probes were developed and tested: a Malachite Green aptamer 
and a Cy5/IowaBlk dsRNA. 
2.3.2 Malachite Green aptamer design and production 
Recent experiments have led to the discovery of RNA aptamers capable of selectively 
binding to the small molecule dye, Malachite Green.71  Roger Tsien and co-workers 
hypothesized that when bound to the RNA aptamer, Malachite Green may become fluorescent 
due to the increased rigidity of the molecule in the RNA binding pocket.72  To this effect, they 
measured a 2360 fold increase in fluorescence yield of Malachite Green upon binding to the 
RNA aptamer.  Slight modification of the Malachite Green aptamer could enable it to both bind 
to Malachite Green and act as a substrate for Dicer.  The RNA could be engineered such that 
Dicer cleaved at or near the Malachite Green binding site as determined by the crystal 
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structure.73  Cleavage of the Malachite Green aptamer by Dicer would cause a disruption in the 
binding pocket and a release of Malachite Green.  This release of Malachite Green would cause a 
decrease in fluorescent intensity and that change could be used to measure dicing activity in a 
kinetic assay. This assay should be cost effective and easily scalable to a high-throughput 
fluorescent plate-based screen. 
 
Figure 2.7 Cleavage of Malachite Green aptamer with Dicer.  Left) Malachite Green is 
fluorescent when bound to RNA aptamer; Right) cleavage of aptamer causes release of 
Malachite Green and loss of fluorescence. 
To design the aptamer, the stem portion of the pre-let-7 miRNA was engineered onto the 
ends of the Malachite Green aptamer so that Dicer would cleave the dsRNA near the Malachite 
Green binding pocket.  Thermodynamic stability predictions suggest that the cleaved product 
would no longer be suitable for Malachite Green binding and hence there would be a marked 
reduction in fluorescence.  A complimentary DNA oligonucleotide was ordered and through a T7 
reverse polymerase reaction, the extended Malachite Green aptamer was formed.  The aptamer 
was separated from free rNTPs via electrophoresis and the aptamer was excised and isolated 
from the gel.  The RNA was heated to 95 °C and slowly cooled to allow proper folding of the 
aptamer. 
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Using an excitation wavelength of 595 nm, the fluorescence emission spectra of 
Malachite Green alone and Malachite Green in the presence of the RNA aptamer were obtained 
(Figure 2.7).  This experiment showed that even with the modification from the originally 
published Malachite Green aptamer, the new extended Malachite Green aptamer was still able to 
bind to Malachite Green and that this binding event caused an increase in fluorescence with 
maximal fluorescence emission at 655 nm. 
2.3.3 Shortcomings of Malachite Green aptamer design 
Unfortunately, Malachite Green quickly decomposes in aqueous environments,74 and this 
decomposition also causes a loss in fluorescent signal that is independent of Dicer cleavage.  The 
signal loss is significant even during the short one-hour time frame used for dicing experiments.  
While this signal decay is suboptimal, an experiment done with the proper control could 
deconvolute the signal decay generated from dicing and the signal decay generated from 
decomposition.  The real concern, however, was the lack of signal loss when Dicer was added 
relative to the no Dicer control.  Two possible hypotheses for why there wasn’t increased signal 
loss are that the Malachite Green aptamer was not a suitable substrate for Dicer or that cleavage 
of the Malachite Green aptamer did not result in the release of Malachite Green from its binding 
pocket and therefore a reduction in fluorescence intensity (Figure 2.8). 
2.3.4 Results from dicing experiments with Malachite Green aptamer 
To determine whether or not Dicer was able to cleave the Malachite Green aptamer, 
Dicer and the aptamer were co-incubated in the absence of Malachite green for one hour, at 37 
°C.  After the hour incubation, Malachite Green was added to the mixture of the uncleaved and 
the cleaved Malachite Green aptamer and the fluorescence emission was measured at 655 nm.  A 
clear dose dependent decrease in fluorescent signal with increasing concentrations of Dicer was 
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observed (Figure 2.8).  This showed that Dicer was able to cleave this extended Malachite Green 
aptamer and that the cleaved aptamer was unable to bind to the Malachite Green (Figure 2.9). 
 
Figure 2.8 Results from Malachite Green aptamer based fluorescent assay.  A) Emission 
spectra (645-700 nm) of the aptamer, Malachite Green alone, and Malachite Green bound 
to the aptamer upon excitation with 595 nm light.  B) Decrease in fluorescence intensity 
with increasing concentrations of Dicer. 
From these experiments, it seems most likely that Dicer does in fact cleave this extended 
Malachite Green aptamer, however, when Malachite Green is present, Dicer is either unable to 
cleave the aptamer or it cleaves the aptamer and the Malachite Green stabilizes the bound 
confirmation, which results in Malachite Green not being released.  The second method, in 
which cleavage of the extended Malachite Green aptamer occurs in the absence of Malachite 
Green would be a very cost effective method to measure cleavage activity of Dicer in a high-
throughput plate based assay.  This method, however, is not a continuous kinetic assay.  In 
addition, a positive result in this assay is a loss of signal and screens utilizing a loss of signal 
readout tend to be hampered more frequently by false positives than screens with enhancement 
of signal. 
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Figure 2.9 Proposed mechanism for the results obtained with the Malachite Green 
aptamer.  Left) When Malachite Green is bound to the aptamer, Dicer cleaves the aptamer, 
but the Malachite Green stabilizes the bound conformation, and the dissociation of 
Malachite Green from the aptamer becomes rate limiting.  The change in fluorescence 
therefore is measuring the rate of dissociation of the cleaved RNA from Malachite Green 
rather than measuring the dicing rate.  Right) If however, the aptamer is cleaved by Dicer 
and the Malachite green is added after cleavage, The Malachite Green is unable to bind to 
the cleaved aptamer and the amount of remaining uncleaved aptamer can be calculated.  
2.3.5 Future directions with dicing rate detection using aptamer based probes 
This method has potential to yield a cost-effective screen for compounds that modulate 
Dicer’s activity if it is modified in such a way that allows for kinetic reads.  Two other 
oligonucleotides were ordered to make derivatives of the extended Malachite Green aptamer 
with different predicted cut sites.  These alternate cut sites are even closer to the Malachite Green 
binding pocket and this cleavage may force Malachite Green to be released, unable to stabilize 
the bound conformation.  This rapid dissociation would enable rate determination of dicing in a 
continuous readout.  Since Malachite Green has stability issues in aqueous environments, another 
oligonucleotide was also ordered to generate a modified Sulforhodamine B (SRB) aptamer.72  
Less is known about the structure of the SRB aptamer since it has not been crystallized, so it may 
take more optimization to determine the correct length of the additional dsRNA bases to position 
the cleavage site near the SRB binding site.  The SRB aptamer has promise though due SRB’s 
increased stability in aqueous environments and would prevent the uncertainty associated with 
signal decay. 
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Due to the low cost of Malachite Green and SRB, and the ease of synthesis of the RNA 
aptamer via in vitro transcription, with optimization this application has the potential to be a 
robust assay to detect modulators of dicing activity.  The loss of signal is not ideal, but an RNA 
aptamer could be designed where the bound small molecule has quenched fluorescence, but upon 
cleavage and release, the molecule becomes increasingly fluorescent.  DNA aptamers have been 
designed that have a similar mechanism,75 but an RNA aptamer rather than a DNA aptamer must 
be designed if it is to act as a substrate for Dicer. 
2.3.6 Cy5/IowaBlk dsRNA probe 
Due to some of the drawbacks of the Malachite Green aptamer design and the time 
investment necessary to fully develop an ideal aptamer based strategy, a new strategy was 
pursued based on a fluorescent-quencher based assay recently developed by Di Nitto et al.76  
They determined which 2 nt 3’ overhangs of dsRNAs were the most efficient substrates for 
Dicer.  Even though their intent was not to design an assay to screen for Dicer activators, this is a 
potential kinetic assay that could be adapted to screen for small molecule or peptide based 
activators of Dicer. 
Two RNA strands were ordered; one strand was conjugated to Cy5 while the other was 
conjugated to an IowaBlk quencher.  When these strands are annealed, the fluorescence from 
Cy5 is quenched (Figure 2.10).  When Dicer cleaves the dsRNA substrate, the cleaved strands of 
RNA are thermodynamically unstable at the assay temperature of 30 °C and the Cy5 and 
IowaBlk dissociate resulting in increased fluorescence.  
After annealing the two RNA strands, a decrease in the fluorescence intensity was 
observed.  Addition of Dicer caused a dose-dependent increase in fluorescent signal, while the 
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mock-transfected (no Dicer) control was unable to cause an increase in fluorescent intensity 
(Figure 2.11). 
 
Figure 2.10 Cy5/IowaBlk probe design.  A) dsRNA labeled with a Cy5 fluorophore and an 
IowaBlk quencher is treated with Dicer.  After cleavage of the dsRNA, the short RNA 
oligonucleotides containing Cy5 and the IowaBlk dissociate at the assay temperature of 30 
°C since their Tm is 22 °C.  The dissociation of the probes causes an increase in 
fluorescence intensity.  B) Fluorescence emission of Cy5 labeled RNA alone and 
fluorescence emission of annealed RNA. 
Figure 2.11 Treatment of Cy5/IowaBlk with A) Ni-NTA purified Dicer or B) Ni-NTA 
purified contaminating proteins from mock transfection.  A) Incubation of various 
concentrations of Dicer (nm) result in an increase in fluorescence intensity over time as 
Dicer cleaves the dsRNA probe.  B) No increase in fluorescence intensity is observed when 
dsRNA is treated with contaminating proteins from mock-transfected SF9 cells, however 
the increased protein content does eliminate the observed signal decay.      
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2.3.7 Signal decay complications of Cy5/IowaBlk dsRNA probe 
As conditions for this assay were optimized, it became clear that a decay of the Cy5 
signal made it difficult to accurately determine the rate of cleavage of the dsRNA.  A number of 
experiments were performed to determine the source of the signal decay.  Temperature, 
evaporation, and light exposure were ruled out as the major source of signal decay.  Cy5 has 
been reported to be susceptible to degradation through ozonolysis with atmospheric ozone.77,78  
Initially, it seemed as if ozonolysis of Cy5 was the most likely source of signal decay, but it 
became clear with additional experimentation that increased protein content in the well had a 
protective effect on signal decay.  The contaminating proteins from the mock-transfection and 
purification prevented signal decay (Figure 2.11).  This phenomenon could only be explained if 
the proteins were protecting the RNA from the causative agent of signal loss or they were 
sequestering the causative agent from the Cy5.  Further experiments showed that not only did 
non-specific proteins prevent signal loss, but Bovine Serum Albumin (BSA) (Figure 2.12) or 
detergents Tween-20 (Data not shown) and Triton-X 100 (Figure 2.13) prevented signal loss of 
both the annealed RNA and the Cy5 RNA alone.  Compiling all of the data, it appears that the 
most probable cause of signal loss is the binding of the RNA probe to the plastic in the 384-well 
plates, which reduces the effective concentration of the RNA probe and therefore the 
fluorescence emission.  This explanation reconciles the observations that proteins and detergents 
prevent signal loss because both of these are known to prevent biomolecules from interacting 
with surfaces.  While this interaction between the dsRNA and the surface of the well seems to be 
the most likely explanation for the signal loss, all other possibilities cannot be ruled out. 
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Figure 2.12 BSA prevents signal decay.  Left) Signal decay with Cy5 RNA alone.  Right) 
Signal decay with annealed RNA. 
 
 
Figure 2.13 Triton X-100 prevents signal decay.  Left) Signal decay with Cy5 RNA alone.  
Right) Signal decay with annealed RNA. 
2.3.8 Future directions with Cy5/IowaBlk probe 
Unfortunately, over the period of a few months, the RNA substrates partially 
decomposed.  Only a small portion of the labeled RNA remained in a condition such that it was a 
suitable substrate for Dicer cleavage.  Therefore, only a 20% restoration in the fluorescence of 
the Cy5 labeled RNA was observed when the annealed RNA was treated with Dicer.  
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Experiments early on with undegraded RNA showed that there was a much larger increase in 
fluorescent signal possible.  These early experiments suffered however from signal loss from the 
RNA binding to the surface of the 384 well plate.  Now that signal loss may be prevented with 
detergents or BSA, a new set of labeled RNAs can be ordered and the rate constants of the 
purified Dicer with this substrate may be determined. 
This assay is nearing complete optimization and it appears that it could be scalable to use 
in high-throughput screen.  The assay is sensitive and kinetic.  Addition of detergents is not a 
setback; in fact many screens are performed in the presence of detergents to prevent false 
positives from aggregating small molecules.79,80  The scale may be limited due to the high costs 
associated with ordering custom RNA oligonucleotides but decreasing the quantity of RNA 
needed while maintaining meaningful signal may be possible with a more sensitive fluorimeter. 
2.4 Expression of TRBP as a positive control for Dicer activation 
2.4.1 TRBP is an endogenous activator of Dicer 
When TRBP binds to Dicer, there is an increase in dicing activity.  Doudna and 
coworkers demonstrated that Dicer in the absence of the helicase domain is much more efficient 
at cleaving RNA substrates.53  They hypothesized that the helicase domain is autoinhibitory.  
TRBP appears to relieve this autoinhibition caused by the helicase domain or alternatively it may 
help in the recruitment of dsRNA substrates to Dicer or regulation of protein stability.  No 
studies have been reported that describe the global conformational changes induced in Dicer 
upon TRBP binding.  Despite an incomplete understanding of how TRBP activates Dicer, a 
small molecule or peptide may be able to induce the same conformational changes and enhance 
Dicer’s ability to cleave pre-miRNAs and to stabilize Dicer in cells deficient in TRBP. 
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2.4.2 Cloning, expression and purification of TRBP 
As a proof of concept experiment and to validate claims that TRBP is capable of 
enhancing Dicer’s catalytic activity, TRBP was expressed and purified.  We obtained a pFastBac 
containing human TRBP from Dr. Qinghua Liu.  The pFastBac was transformed into DH10Bac 
competent cells and the bacmid DNA was purified, and transfected into SF9 cells following the 
same procedure used for preparing the recombinant Dicer baculovirus. 
After generation of the TRBP baculovirus and subsequent amplification, 25 mL of the P3 
amplified baculovirus was used to infect 600 mL of exponentially dividing (2x106 cells/mL) SF9 
cells.  After 72 hours the cells were harvested, lysed, and purified by Ni-NTA affinity 
chromatography using the same procedure as used for Dicer.  The TRBP was further purified 
using size exclusion chromatography.  After size exclusion, TRBP was approximately 70% pure 
and ready for further use. 
 
Figure 2.14 Coomassie stain of heterologous expression and purification of human TRBP 
from suspension SF9 cells.  L=0.2x lysate, CL=0.2x cleared lysate, FT=0.2x flow-through, 
W1=first wash, W5=fifth wash, E=elution. 
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Figure 2.15 Analysis of purification of TRBP on size exclusion chromatography.  A) UV 
trace (280 nm) of size exclusion purification of TRBP.  B) SyproRuby analysis of fractions 
from size exclusion purification of TRBP.  C) Densitometry to estimate purity of TRBP in 
the three indicated fractions. 
2.4.3 Testing TRBP in dicing assay 
When TRBP was added to the dicing mixture no increase in cleavage of the fluorescently 
labeled dsRNA was observed.  This is not surprising because according to Chakravarthy et al. 
TRBP alone may actually inhibit Dicer’s activity because the dsRBDs may sequester the RNA 
from Dicer and prevent its cleavage.62  They report that the complex must be pre-formed 
between Dicer and TRBP.  In their experiments, they formed the complex between Dicer and an 
excess of TRBP.  The excess TRBP was separated from the Dicer-TRBP complex by size 
exclusion chromatography.  This pre-formed complex was compared to Dicer alone in their 
dicing experiments and showed enhanced cleavage. 
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2.4.4 Future directions with TRBP 
Now that TRBP and Dicer have been purified to >60% it may be possible to form this 
complex between TRBP and Dicer.  Once the complex is formed and the exact concentration of 
Dicer is determined, the rates of cleavage of Dicer alone to the Dicer-TRBP complex can be 
compared.  It is critical to demonstrate that the cleavage of fluorescent-based substrate used in 
this assay can also be enhanced by TRBP in the same way that TRBP enhances the cleavage of 
pre-miRNAs.  Once the fold enhancement of dicing in the presence of TRBP has been 
determined, this can be used as a benchmark to determine the amount of activation needed with 
small molecules or peptides to induce a similar biological effect as TRBP in cells. 
2.5 Peptide mapping of C-terminus of TRBP 
2.5.1 Interaction of C-terminus of TRBP and Dicer’s helicase domain 
Full length TRBP is known to enhance Dicer’s activity, but only the 69 C-terminal amino 
acids (298-366) of TRBP are required for binding to Dicer.58  Testing this C-terminal domain to 
determine if it would not only bind to Dicer but if it enhanced Dicer’s activity is critical in 
understanding TRBP’s mode of action.  If this C-terminal domain of TRBP is insufficient for 
activation of Dicer, but is shown to still bind to Dicer, this would suggest that the dsRBD1 and 
dsRBD2 are essential for the activation of Dicer and that TRBP may facilitate passage of the pre-
miRNAs into the active site or transfer of the mature miRNAs from the active site to Ago2.81,82 
Chakravarthy et al. expressed this domain in E. coli and reported that it did not activate 
Dicer.62  No data is shown to confirm binding between the C-terminal domain of TRBP and the 
helicase domain of Dicer.  Additionally it is difficult to determine if the C-terminal domain that 
was expressed was correctly folded because no structural information exists on this domain.  
Understanding the interaction between the C-terminal domain of TRBP and Dicer is critical in 
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the development of a small molecule or peptide activator of Dicer.  If this 69 amino acid domain 
is capable of activating Dicer, a small molecule or peptide could reasonably mimic its mode of 
action and therefore a therapeutic could be developed.  If, on the other hand, this 69 amino acid 
domain is shown to bind to Dicer and there is no activation, this implies that full length TRBP is 
necessary for activation.   Mimicking the mode of action of a multi-domain protein with a small 
molecule or a peptide would be significantly more challenging. 
2.5.2 Design and cloning of C-terminal domain 
Expression of the C-terminal domain of TRBP was designed to determine its binding 
affinities to the helicase domain of Dicer and to see if this domain could enhance Dicer’s 
activity.  Primers were ordered with engineered BamHI and Xhol restriction sites as well as stop 
codons.  These primers were used to amplify the C-terminal portion of TRBP in a PCR reaction.  
(Note:  Due to an error in primer design, only the last 68 amino acids (299-366) of TRBP were 
amplified and cloned rather than the full 69 amino acids (298-366)).  After amplification of the 
C-terminal domain, the amplicon and the pET28b+-mbp vector were sequentially digested using 
BamHI and Xhol.  The cut fragments were gel extracted and ligated using T7 DNA ligase.  The 
ligated plasmid was transformed into turbocompetent DH5α cells.  The plasmid DNA was 
isolated from an overnight culture and sequenced to verify correct insertion of the TRBP C-
terminal domain into the vector. 
This pET28b+-mbp (TRBP 299-366) contains a fusion protein between MBP and the C-
terminal domain of TRBP separated by a TEV protease site. Peptides are frequently difficult to 
express and are susceptible to proteases; therefore, the peptides were fused to MBP to increase 
their expression levels and provide additional stability.  The peptide is designed such that after 
cleavage of the fusion protein with TEV protease, the peptide is released and contains an 
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additional 2 amino acids on the N-terminus: a glycine and a serine.  The final peptide product is 
gly-ser-TRBP (299-366). 
After the fusion construct was designed and cloned, the correct gene insertion was 
verified by PCR.  The plasmid was transformed into Rosetta cells.  The fusion protein was 
expressed by inducing cells at an OD600 of 0.5-0.7 with 1 mM IPTG.  The cells were grown at 
37 °C for four hours and shaking at 250 rpm.  The cells were harvested and lysed and the fusion 
protein was concentrated and dialyzed into a low imidazole buffer.  The concentrated and 
dialyzed fusion protein was treated with TEV protease expressed in-house.  After TEV cleavage, 
the mixture was again purified by Ni-NTA purification, except this time the C-terminal domain 
of TRBP was not retained on the column but is collected in the flow through and washes.  The 
TEV protease and the MBP both contain the His6 affinity tags and may be eluted with higher 
concentrations of imidizole.  This process should result in relatively pure peptides that can be 
further purified by reverse phase chromatography using a C18 prep scale column on an HPLC. 
2.5.3 Expression and purification of TRBP peptides 
This process of production of peptides was repeated for ten different constructs.  This 
method may be used to further define the region of TRBP that is capable of interacting with the 
helicase domain of Dicer.  To define the minimal sequence necessary, this peptide mapping 
based approach may be successful (Figure 2.16).  Ten overlapping 30 amino acid peptides were 
designed that span the 68 amino acid region from 299-366.  Each peptide begins five amino 
acids after the previous peptide.  The peptides that were designed include: 299-328, 304-333, 
309-338, 314-343, 319-348, 324-353, 329-358, 334-363, and 339-366.  Using these peptides, the 
minimal region of TRBP required for binding to Dicer’s helicase domain may be determined.  If 
such a peptide were identified, more peptides would be ordered or designed that would further 
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characterize the critical amino acids required for TRBP’s interaction with Dicer.  It is also 
entirely possible, however, that the entire 69 amino acid domain is required for the interaction 
between TRBP and Dicer, and that tertiary contacts within this domain are necessary to maintain 
the proper fold.  There are many questions about this approach but currently; no reports exist of 
anything smaller than the C-terminal 69 amino acid domain interacting with Dicer.58 
Figure 2.16 Peptide mapping design of TRBP.  Full length TRBP (1-366), the CTD (299-
366) and ten overlapping 30 amino acid peptides will all be tested for their ability to 
activate Dicer. 
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2.5.4 TRBP (339-366) 
The same cloning and expression procedures were followed for each of the ten peptides.  
Primers were ordered; the genes were cloned, sequenced and transformed into Rosetta.  Here, the 
purification of one of the peptides TRBP (339-366) is demonstrated.  The fusion protein was 
expressed the same as was done for TRBP (299-366).  MBP-TRBP (339-366) was purified by 
Ni-NTA chromatography and was analyzed by MALDI mass spectrometry (Figure 2.17).  The 
protein was concentrated and dialyzed and then treated with TEV protease.  After treatment with 
TEV protease, the mixture was analyzed by MALDI mass spec and it was verified that TRBP 
(339-366) was formed and that there was a proportionate decrease in mass of the full-length 
protein (Figure 2.18). The peptide was separated from the MBP and the TEV using Ni-NTA 
affinity chromatography and each of the fractions were analyzed by MALDI mass spectrometry 
(Figures 2.19 & 2.20).  It was confirmed that the TRBP (339-366) peptide was present in the 
flow-through and first wash.  These fractions were combined and the peptide was desalted and 
purified by prep HPLC on a C18 reverse phase column using a gradient from 5-95% acetonitrile 
with 0.1% TFA in HPLC grade water containing 0.1% TFA (Figure 2.21).  Fractions containing 
each peak were analyzed by MALDI mass spectrometry and peak B was confirmed to be the 
correct mass (3194 Da) (Figure 2.22).  In summary, this procedure was successful in producing 
and purifying TRBP (339-366) that can be used for binding studies with Dicer by isothermal 
titration calorimetry or surface plasmon resonance.  This fragment will also be used in the 
Cy5/IowaBlk dicing assay to determine if is capable of enhancing Dicer’s activity.  
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Figure 2.17 Expression and purification of MBP-TRBP(339-366) fusion protein from E. 
coli.  CL=cleared lysate, FT=flow-through, B=wash with binding buffer, W=wash with 
wash buffer, E=elution.  
 
Figure 2.18 MALDI mass spectrometry analysis of MBP-TRBP(339-366) before and after 
TEV cleavage. 
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Figure 2.19 TEV cleavage and reverse Ni-NTA purification of TRBP(339-366).  Before 
Cleavage=concentrated fusion protein before treatment with TEV protease, After 
Cleavage=concentrated fusion protein after treatment with TEV protease, FT=flow 
through of reverse Ni-NTA, W=wash of reverse Ni-NTA, E=elution of reverse Ni-NTA, 
Before Cleavage=diluted fusion protein before TEV cleavage. 
 
 
Figure 2.20 MALDI mass spectrometry analysis of fractions of reverse Ni-NTA 
chromatography after TEV cleavage of MBP-TRBP(339-366) 
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Figure 2.21 UV trace of HPLC purification of TRBP(339-366).  Blue trace is wash buffer 
only; black trace is the flow-though of the reverse Ni-NTA purification after TEV cleavage. 
 
Figure 2.22 MALDI mass spec analysis of TRBP(339-366) after HPLC purification and 
desalting. 
2.5.5 Purification attempts of remaining peptides 
This purification procedure was attempted for four other peptides distributed across the 
C-terminal domain (299-328, 309-338, 319-348, and 329-358).  In each of these cases the 
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desired peptide was not obtained.  This was attempted multiple times, and in all instances 
expression of 339-366 was achieved and expression of (299-328, 309-338, 319-348 and 329-
358) was not achieved.  Analyzing the MALDI mass spectrometry data, it appears that in the 
cases of these other four fusion proteins, even the mass before cleavage does not correspond to 
the correct mass.  This suggests that during expression or purification of the fusion protein, 
proteases are cleaving these peptides. 
2.5.6 Structural considerations in purification of TRBP peptides 
Using a CDM secondary structure prediction algorithm, the secondary structure of the 
299-366 domain was predicted (Figure 2.23).83  The predicted structure contains three β-sheets 
and one α-helix.  This predicted structure is in close alignment with the dsRBD I and dsRBD II 
which, have an α-β-β-β-α domain structure.61  These domains have a 40% amino acid similarity, 
which means it is possible that the C-terminal domain of TRBP has a similar fold as the two 
dsRBDs, but it is also equally plausible that its domain architecture is radically different.  Since 
this C-terminal domain has a distinct biological function from the two dsRBDs, it cannot be 
assumed that they have the same fold.  Despite the possibility that they may form different folds, 
the CDM structure prediction is robust for α-helices and amino acids 348-361 are likely to be α-
helical, which may promote the stability of TRBP (339-366).  The other peptides may lack 
secondary structure, which renders them more susceptible to proteases.  This structural stability 
may partially explain why purification of TRBP (339-366) is possible while TRBP (299-328, 
309-338, 319-348 and 329-358) remains elusive. 
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Figure 2.23 Secondary structure prediction of C-terminal domain of TRBP.  Note the 
similar predicted fold as the other dsRBD domains of TRBP (α-β-β-β-α) 
2.6 Conclusions and future directions 
Activation of Dicer still remains a work in progress.  Many improvements have been 
made on expressing and purifying Dicer, and now Dicer can be purified to >60% purity as 
assessed by SYPRORuby.  Further work must be performed to completely purify Dicer and 
optimization of the reverse Ni-NTA purification after TEV cleavage may yield uniformly pure 
Dicer.  The same procedures that may enhance the purity of Dicer may also be applied to the 
purification of TRBP, which currently can be purified to >60% purity as assessed by 
SYPRORuby.  Once Dicer and TRBP are completely purified, a complex may be formed 
between the two proteins and tested in a dicing assay to verify previous reports that TRBP 
enhances Dicer’s cleavage activity.  Once TRBP has been shown to activate Dicer, this will set a 
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benchmark for activity of all small molecule or peptide based activators of Dicer.  Two assays 
have been developed to assess Dicer activity that may be used in a plate based fluorescent 
screen.  The first of which is a novel Malachite Green aptamer based assay.  This assay is very 
cost effective and holds great promise with a few modifications.  The second assay, the 
Cy5/IowaBlack RNA based assay is nearing complete optimization.  The addition of Tween-20 
or TritonX-100 at a concentration of 0.01% prevents a majority of the signal decay.  While this 
assay is effective, the cost of synthesis of modified RNA strands remains high, and increasing 
the scale to a full high-throughput screen may be cost prohibitive. Once TRBP is shown to 
enhance Dicer’s activity, a needle in a haystack experiment may be performed to verify that this 
screen is capable of detecting activators of Dicer in a 384-well plate based format. 
The cloning and expression of eleven peptides has been completed (299-366, 299-328, 
304-333, 309-338, 314-343, 319-348, 324-353, 329-358, 334-363, 339-366).  The process of 
purifying these peptides was verified using TRBP (339-366); however, the other peptides have 
not been purified.  These peptides may have increased susceptibility to proteases due to a lack of 
secondary structure.  Some possible pathways forward include purchasing peptides produced by 
solid phase synthesis, or using protease inhibitors during the lysis and purification of the fusion 
protein.  Once each peptide is purified, they will be tested for their ability to bind to Dicer’s 
helicase domain using isothermal titration calorimetry and surface plasmon resonance to further 
define the epitope of TRBP that interacts with Dicer.  These peptides will also be tested with 
Dicer Δhelicase to verify that they do not bind to Dicer when the helicase domain is absent. 
Dicer, TRBP, TRBP peptides and an assay are all nearing completion and will soon be 
ready to further define the interaction between TRBP and Dicer as well as potentially identify 
small molecules or peptides that are able to enhance Dicer’s cleavage activity.  These 
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therapeutics will be further tested to validate Dicer as a therapeutic target in cancers containing 
deficiencies in miRNA processing. 
 
 54 
 
3 Material and Methods 
3.1 Recombinant bacmid and baculovirus production 
pFastBac transformation 
Three recombinant pFastBacs were obtained from Dr. Jennifer Doudna containing full-
length human Dicer, hDcr, Dicer lacking the helicase domain, ∆Helicase, and a full-length 
mutant containing an inactive helicase domain, hWalker.  Additionally, full-length recombinant 
TRBP pFastBac was obtained from Dr. Qinghua Liu.  2 µL of each plasmid was gently added to 
100 µL of competent DH10Bac E. coli cells that were pre-thawed on ice. Following a 30 min 
incubation on ice, the cells were heat shocked in a 42 °C water bath for exactly 45 seconds and 
then immediately returned to ice and incubated for 5 min.  1 mL of S.O.C. media (rt) was added 
to the cells and incubated at 37 °C for 4 hours at 250 RPM.  100 µL of the cell suspension was 
then plated onto an LB/Agar plate containing 50 µg/ml kanamycin, 7 µg/ml gentamicin, 10 
µg/ml tetracycline, 100 µg/ml Bluo-gal, and 40 µg/ml IPTG.  The plates were incubated 
overnight at 37 °C.  Each colony was carefully examined to verify that it was a true white colony 
and did not contain any blue, and 10 white colonies were selected from each construct and they 
were restreaked onto an LB/Agar plate containing 50 µg/ml kanamycin, 7 µg/ml gentamicin, 10 
µg/ml tetracycline, 100 µg/ml Bluo-gal, and 40 µg/ml IPTG to verify that each was a true white 
colony.  
Bacmid purification 
A colony was selected from the restreak plate and transferred to 12 mL of LB containing 
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50 µg/ml kanamycin, 7 µg/ml gentamicin, and 10 µg/ml tetracycline in a 50 mL conical vial. The 
culture was grown 12 -16 hours at 37 °C at 250 RPM.  The cells were then centrifuged at 500 g 
for 5 min.  The supernatant was removed and 700 µL of Quiagen’s P1 (resuspension buffer) was 
added and the cells were resuspended by vortex.  The cell suspension was then transferred into 
(2) 1.5 mL eppendorf tubes in 400 µL aliquots.  Next, 450 µL of buffer P2 (lysis buffer) was 
added to each tube, and the cells were gently mixed by inverting the tubes 10 times.  550 µL of 
buffer N3 (neutralization buffer) was immediately added and the tubes were inverted 20 times or 
if using lyse blue until all of the blue color disappears from solution.  The cellular debris was 
then removed by centrifugation at 14,100 g on a tabletop centrifuge for 10 min.  The supernatant 
was then poured into fresh 1.5 mL eppendorfs carefully avoiding any white precipitate.  These 
centrifuge tubes were subjected to another round of centrifugation and decanting to completely 
remove any cellular debris.  The supernatant was poured into an equal volume of ice-cold 
isopropanol, and the DNA was precipitated by freezing the eppendorf in a dry ice and acetone 
bath.  The tubes were thawed on ice and then centrifuged at 21,000 g on a tabletop centrifuge for 
10 min at room temperature.  The supernatant was removed and the DNA pellet was washed 
with 1 mL of 70% ice-cold ethanol and centrifuged again at 21,000 g for 5 min at room 
temperature.  The 70% ethanol was poured off and the pellet was air dried for 10 min.  Next, 50 
µL of 10 mM Tris Buffer (pH 8.0) was added to the DNA pellet and gently resuspended by 
flicking the tube.  The DNA was quantified by measuring the absorbance at 260 and 280 nm and 
typical concentrations were 1-2 µg/mL bacmid DNA with an Abs 260: Abs 280 ratio around 1.8.  
The bacmid DNA may be stored for up to 2 weeks at 4 °C, do not freeze bacmid DNA. 
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PCR verification of bacmid 
Verification that the Dicer or TRBP genes were correctly inserted into the bacmid DNA 
was performed by PCR.  In a PCR tube, the following were added: 7.5 µL of 10X Pfu 
amplification buffer, 10 µL of 8mM dNTPs (2 mM each), 500 ng of bacmid DNA, 0.7 µL of 10 
µM M13 forward primer and 0.7 µL of 10 µM M13 reverse primer, 5 U of PfuUltra polymerase, 
and enough MilliQ water to make the final volume 50 µL.  The tube was heated to 94 °C for five 
minutes followed by 30 cycles of: 94 °C for 15 seconds, 55 °C for 30 seconds, and 68°C for 20 
minutes.  A final extension at 68 °C for 90 minutes was performed before cooling the PCR 
reaction to 4 °C.  The PCR product was directly analyzed by agarose gel electrophoresis.  The 
correct PCR product is the length of the gene insert + 2440 base pairs.   
Transfection 
The media was removed from a T-75 flask containing 80% confluent SF9 cells grown in 
20 mL of ESF-921 media with 5% FBS and 0.7x Pen/Strep.  The media was replaced with 10 
mL of ESF-921 media without antibiotics or FBS.  The cells were scraped and gently 
resuspended.  The cells were counted in a hemocytometer and diluted to 5x105 cells/mL.  2 mL 
of cells (1 x 106 cells) were added to 2 wells of a 6-well tissue culture plate and the plate was 
incubated at 27 °C for 1 hour to allow the cells to attach.  After the cells attach, they should be 
approximately 50% confluent.  The media was removed by aspiration and immediately replaced 
with 2.5 mL of Grace’s insect cell media, unsupplemented and without antibiotic.  100 µL of 
Grace’s unsupplemented media was added to (4) 1.5 mL Eppendorf tubes.  8 µL of Cellfecten II 
transfection reagent from Invitrogen was added to the 100 µL of Grace’s media in two of the 
Eppendorf tubes.  1 µg of purified recombinant bacmid DNA was added to 100 µL of Grace’s 
media in another Eppendorf tube and no DNA was added to the other Eppendorf tube as a 
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negative control.  The two tubes containing cellfectin II were briefly vortexed and then they were 
gently added to the other Eppendorf tubes containing recombinant bacmid or no DNA control.  
The mixture incubated at room temperature for 30 minutes and then was added drop-wise onto 
the cells in the 6 well plate.  After a 3 hour incubation at 27 °C, the media was removed and 
replaced with 2.5 mL of fresh ESF-921 containing 5% FBS and 0.7x pen/strep.  The 6 well plate 
was placed inside a zip lock bag containing paper towels wetted with MilliQ water to provide a 
humidified environment and incubated for 7 days at 27 °C.  The supernatatnt, which contains the 
recombinant baculovirus (P1), is collected and stored away from light at 4 °C and remains stable 
for months, long term storage of the baculovirus is possible at -80 °C but, freeze-thawing the 
baculovirus can reduce viral titer by an order of magnitude.   
Plaque assay 
This procedure is used to titer the initial P1 baculoviral stock or any subsequent 
amplifications.  The media of a T-75 flask containing healthy SF9 cells at about 80% confluence 
was replaced with 10 mL of fresh ESF-921 containing 5% FBS and 0.7x pen/strep.  The cells 
were scraped and counted with a hemocytometer and diluted to 5 X 105 cells/ml.  2 mL of cells 
were added to each well of a 6 well tissue culture plate and the cells were allowed to adhere for 1 
hour in the tissue culture hood without disruption.  After the hour incubation, the cells were 
inspected by a light microscope to confirm that they were evenly distributed throughout the wells 
and at about 50% confluency.  The baculovirus was serially diluted using fresh ESF-921.  The 
media from the 6 well plate was removed and it was gently replaced, as to not disrupt the 
monolayer of cells, with 1 mL of baculovirus dilutions 10-4, 10-5, 10-6, 10-7, and 10-8 and a no 
virus control.  The baculovirus dilutions were incubated with the cells for exactly 1 hour at 27 
°C.   50 mL of 4% low melting point agarose was autoclaved in a 250 mL Erlenmeyer flask.  A 
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water bath was disinfected and pre-warmed to 42 °C.  15 mL of 1.3x Grace’s media containing 
10% FBS and 0.7x pen/strep was warmed to 42 °C.  5 mL of the 4% low melting point agarose 
was added to the 15 mL of 1.3x Grace’s media and the combination was incubated at 42 °C.  
After the hour incubation of baculovirus with the cells, the cells were washed with 2 mL of ESF-
921 containing 5% FBS and 0.7x pen/strep.  The media was removed and immediately and 
gently replaced with 2 mL of the agarose overlay.  The plate was placed inside a zip lock bag 
containing wetted paper towels and was incubated for 10-13 days at 27 °C.  After 10-13 days the 
plaques become visible to the naked eye as small light colored specs. 
Visualizing plaque assay and determining titer 
To better visualize the plaques, Neutral Red staining solution may be used to stain the 
remaining live cells after 10 days.  500 µL of 0.33 mg/mL Neutral Red in MilliQ water is added 
over the agarose overlay of each well in the 6 well tissue culture plate.  The plate is incubated for 
1 hour at 27 °C and then the Neutral Red solution is removed.  After another 2 hour incubation at 
27 °C following dye removal, the plate is visualized on a Bio-Rad gel docking station and the 
plaques are counted.  The optimal range for counting of plaques in a well is 3-20, titer is 
determined by the following equation: Titer (pfu/mL) = 1/dilution factor * # plaques * 1/(mL of 
innoculum).  A good amplified baculoviral stock contains a titer around 1x108 pfu/mL. 
Baculovirus amplification 
The baculovirus may be reliably amplified up to P3, after which there may be an 
accumulation of partially packaged baculovirus genomes resulting in defective interfering 
particles (DIPs) that are incapable of expressing protein.  Amplification of the baculovirus may 
be performed in both adherent cells and suspension cells, however to generate enough 
recombinant baculovirus for large-scale expression, this amplification must be done in 
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suspension cell culture.  500 mL of exponentially dividing cells (1.5 – 2.0 x 106 cells/ml and 
>95% cell viability) growing in a 1L spinner flask were infected with 1 mL of recombinant P1 
baculovirus.  Cell count was measured daily, after 24 hours the cell count increased slightly to 
2.5-3.0x106 cells/ml and remained constant for the next 48-72 hours.  The cell suspension was 
collected after a 50% drop in cell viability, typically 5 to 6 days post infection.  The 500 mL was 
transferred into (10) 50 mL conical vials and was centrifuged at 500 g for 5 min.  The 
supernatant was collected and transferred to fresh 50 mL conical tubes and stored at 4 °C, this is 
the P2 baculoviral stock.  The virus may also be stored long term at -80 °C; however, viral titer 
will be significantly decreased upon thawing. 
3.2 SF9 cell culture 
Beginning a new stock of SF9 cells 
1x107 SF9 cells from Novagen were rapidly thawed in a 37 °C water bath and transferred 
to a T-75 tissue culture flask containing 20 mL of ESF-921 media with 5% FBS and 0.7x 
pen/strep and incubated for 4 hours at 27 °C.  After the 4 hour incubation, some of the cells had 
attached and the remaining media and loose cells were removed and replaced with 20 mL of 
fresh ESF-921 supplemented with FBS and antibiotic.  The cells were grown until they reached 
confluency and the media was replaced every 3-4 days. 
Passaging adherent SF9 cells 
Once cells reached 100% confluency, the media was replaced with 10 mL of fresh ESF-
921 containing 5% FBS and 0.7x pen/strep.  The cells were dislodged from the flask using a cell 
scraper, and the flask was gently agitated to remove aggregated cells.  10 µL of cell suspension 
was added to a hemocytometer and the cell density was determined.  Typically, a T-75 flask that 
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is 100% confluent will contain around 2x107 cells.  1.5-2.0x106 cells were added to a T-75 tissue 
culture flask with 20 mL of ESF-921 media containing 5% FBS and 0.7x pen/strep and incubated 
at 27 °C.  Every 3-4 days the media was replaced with fresh media.  This entire process was 
repeated to always maintain a fresh stock of adherent SF9 cells.  After 30 passages, the SF9 cell 
lines were discarded and replaced with a new stock. 
Adapting adherent SF9 cells to suspension culture 
6x107 exponentially dividing cells from multiple T-75 tissue culture flasks were 
dislodged by scraping and added to 120 mL of ESF-921 media with 5% FBS and 0.7x pen/strep 
in a 125 mL spinner flask for a final concentration of 5x105 cells/mL  The cells were stirred at a 
rate of approximately 250 rpm at 27 °C.  The cells continued to divide until they reached 4-6x106 
cells/ml.  The cells were passaged in suspension by seeding the next passage at a concentration 
of 5x105 cells/mL until the doubling time was approximately 24 hours and the cell viability was 
greater than 95% at which point the cells are fully adapted to suspension cell culture. 
Passaging suspension SF9 cells 
Suspension cells were maintained in the 125 mL spinner flask, and this 125 mL spinner 
flask was used to seed the larger 1 L spinner flask that was used for large-scale expression of 
recombinant proteins.  Once cells reached 4x106 cells/ml in the 125 mL spinner flask, a new 
passage was created of 625 mL of 5x105 cells/mL in ESF-921 with 5% FBS and 0.7x pen/strep.  
125 mL of the cells were poured back into the 125 mL spinner flask, and the remaining 500 mL 
was poured into the 1 L spinner flask.  Each flask was incubated at 27 °C with stirring around 
250 rpm (speed setting: 4 for 125 mL spinner and 5 for 1 L spinner).  The volume of cells in the 
1 L spinner flask must remain at 500-600 mL to provide adequate oxygenation to the cells; if the 
volume is too high, the cells die and appear fragmented when analyzed under the microscope. 
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3.3 Protein expression and purification from SF9 cells 
Protein expression from SF9 cells 
25 mL of 1x108 pfu/mL recombinant baculovirus was added to 500 mL of exponentially 
dividing SF9 cells at a concentration of 1.5-2.0x106 cells/ml.  The cell concentration was 
monitored daily and remained between 1.5-2.0x106 cells/ml.  After 66-72 hours the cell viability 
remained high (about 90%) and the cells were harvested.  The 500 mL cell suspension was 
transferred to 50 mL conical tubes and centrifuged at 500 g for 5 minutes at 4 °C.  The 
supernatant was removed and the cells were resuspended in 5 mL of ice-cold sterile PBS.  The 
resuspended cells from the 10-12 conical tubes were combined into (2) 50 mL conical tubes and 
centrifuged again at 500 g for 5 minutes and 4 °C.  The PBS was poured off and the cell pellet 
was frozen at -20 °C for further use. 
Protein purification 
A frozen pellet containing cells from 250-300 mL of expression was resuspended in lysis 
buffer (50 mM sodium phosphate, dibasic(pH 8.0), 300 mM NaCl, 10 mM imidazole(pH 8.0), 1 
mM TCEP[tris(2-carboxyethyl)phosphine], 0.5% Trition X-100, 5% glycerol) and 100 µL of 
EDTA-free protease inhibitor cocktail III (Calbiochem)  After the pellet was resuspended, the 
cells were lysed with 15 strokes of a 15 mL Dounce grinder (pestle B) on ice.  The lysate was 
centrifuged at 40,000 g for 35 min at 4 °C and the supernatant was collected.   
Ni-NTA purification 
2 mL of Ni-NTA slurry was added to the cleared lysate and was rotated at 4 °C for 4 
hours.  The 50 mL conical vial containing the cleared lysate and the Ni-NTA resin was 
centrifuged at 2,000 g for 1 minute at 4 °C.  The supernatant was poured off and the resin was 
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resuspended with 45 mL of Wash Buffer (50 mM sodium phosphate, dibasic(pH 8.0), 300 mM 
NaCl, 20 mM imidazole(pH 8.0), 1 mM TCEP[tris(2-carboxyethyl)phosphine], 5% glycerol).  
The resin was again pelleted by centrifugation at 2,000 g for 1 min at 4 °C.  The washes were 
repeated 3 times and upon resuspension of the pellet with the fourth 45 mL aliquot of wash 
buffer, the mixture was transferred to a column pre chilled to 4 °C and the resin was allowed to 
settle by gravity flow.  After the resin settled, a fifth wash of 45 mL of wash buffer was added 
over the column and allowed to drain by gravity flow.  To elute the His-tagged protein (hDcr or 
TRBP) 4.5 mL of Elution Buffer (50 mM sodium phosphate, dibasic(pH 8.0), 300 mM NaCl, 
300 mM imidazole(pH 8.0), 1 mM TCEP[tris(2-carboxyethyl)phosphine], 5% glycerol) was 
added to the column and the flow through was collected containing the His-tagged protein (hDcr 
or TRBP) and stored at 4 °C overnight or directly loaded onto an AKTA-FPLC for size 
exclusion purification. 
Size exclusion purification 
A 16-60 S-200 gel filtration column was pre-equilibrated with 2 column volumes (240 
mL) of gel filtration buffer (50 mM HEPES (pH 8.0), 300 mM NaCl, 1 mM TCEP, 5% glycerol) 
at 4 °C.  2 mL of Ni-NTA purified protein were added via syringe without filtering through a 0.2 
µm syringe filter into a 2 mL load loop on an AKTA-FPLC.  The protein was passed through the 
S-200 column with 1.5 CV (180 mL) of gel filtration buffer at a flow rate of 0.6 mL/min.  
Fractions were collected every 5 mL or every 3 mL where absorbance was above 5 mAu.  
Fractions were analyzed by SDS-PAGE and stained with SYPRORuby to determine which 
fractions contained recombinant protein (hDcr or TRBP).  Void Volume – 42 mL, Dicer elution 
volume – 55-65 mL (Kav: 0.23), TRBP elution volume – 65-80 mL (Kav: 0.36), Included Volume 
– 120 mL. 
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TEV cleavage of Dicer or TRBP 
After Ni-NTA purification of Dicer or TRBP, 2.5 mL were added into a 3 mL dialysis 
cassette  (MWCO: 3,000) that was pre-wetted with wash buffer (50 mM sodium phosphate, 
dibasic (pH 8.0), 300 mM NaCl, 20 mM imidazole (pH 8.0), 1 mM TCEP[tris(2-
carboxyethyl)phosphine], 5% glycerol).  The solution was dialyzed overnight in 1 L of wash 
buffer at 4 °C.   The protein was removed from the cassette and transferred to a 15 mL conical 
vial and 50 µL of His-TEV (S219V) (1 mg/ml) was added and incubated overnight at 4 °C.  
Reverse Ni-NTA purification of cleaved Dicer or TRBP 
After removal of His6 tag from Dicer or TRBP, 1.5 mL of Ni-NTA slurry was added to 
the 15 mL conical vial at 4 °C.  The solution was rotated for 2 hours at 4 °C and then the mixture 
was added to a column pre-chilled to 4 °C and allowed to settle by gravity flow, collecting the 
flow through.  The column was then washed twice with 2 mL of wash buffer and then washed a 
third time with 15 mL of wash buffer.  The TEV and contaminant was then eluted twice with 3 
mL of elution buffer (50 mM sodium phosphate, dibasic (pH 8.0), 300 mM NaCl, 300 mM 
imidazole (pH 8.0), 1 mM TCEP[tris(2-carboxyethyl)phosphine], 5% glycerol) All fractions 
were analyzed by SDS-PAGE and Western. Note: This procedure did not work, none of the 
Dicer or TRBP ever eluted in the flow through or washes, and seems to have disappeared, 
possibly due to deposition on the plastic or glass surfaces or it remains attached to the Ni-NTA 
resin. 
Concentrating Dicer using dialysis cassettes 
Dicer is a very “soft” protein that readily sticks to surfaces, and as such it may quickly be 
lost from solution due to attachment to surfaces, especially at higher temperatures.  This 
attachment is especially a problem with cellulose membranes and nearly all of Dicer is lost when 
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it is passed through a 0.2 µm filter.  Additionally, Dicer attaches to the cellulose membrane in a 
concentrating tube and is not present in the flow through or the supernatant.  For this reason, if 
Dicer must be concentrated, it must be done using the principles of osmosis in a dialysis cassette.  
After size exclusion, Dicer is very dilute and must be concentrated to prevent protein loss due to 
surface attachment.  The fractions from size exclusion containing purified Dicer were pooled 
(10-15 mL).  A 15 mL dialysis cassette (MWCO 3,500) was wetted with gel filtration buffer at 4 
°C and placed inside a Tupperware container.  Dicer was added to the dialysis cassette and all air 
bubbles were removed.  2 g of cold PEG 8,500 was placed on the bottom of the Tupperware and 
then the dialysis cassette containing Dicer was placed on top of the PEG 8,500.  An additional 2 
g of PEG 8,500 were added over top of the dialysis cassette to completely cover the membrane.  
Through reverse osmosis, Dicer is concentrated and the gel filtration buffer mixes with the PEG 
8,500 and creates a paste.  After 4-6 hours, the PEG 8,500 is replaced with fresh PEG 8,500 and 
air is added into the dialysis cassette to increase the internal volume of the cassette, if the cassette 
contracts too much, the membrane seals will leak and the protein will be lost.  Carefully 
monitoring the dialysis cassette, this process takes between 16 and 24 hours to reduce the volume 
of the internal solution to 2 mL. 
3.4 Protein analysis and characterization 
Analysis of protein purification by SDS-PAGE 
Every step of protein expression and purification should be carefully monitored by SDS-
PAGE to assess the relative quantity and purity of the protein produced.  10 µL of each fraction 
is mixed with 4 µL of 6x Lammelli SDS load buffer and the samples are boiled at 95 °C for 6 
minutes.  (In cases where protein content was high, ie the lysate and the cleared lysate, only 2 µL 
of the sample was used and it was mixed with 8 µL of MilliQ water to make a 0.2x sample)  
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After the samples were boiled, they were loaded into a 15 well Bio-Rad 4-20% TGX precast gel 
and the samples were run at 120 V for 70 minutes.  Samples were analyzed either by Coomassie 
Blue staining, SyproRuby staining and/or Western blotting. 
Coomassie Blue staining procedure 
The gel was removed from the cassette and was placed in a plastic box containing ~30 
mL of fresh Coomassie stain and the gel was rocked for 2 hours at room temperature.  The 
Coomassie was replaced with ~40 mL of destaining solution and the gel was rocked for 2 hours 
at room temperature.  The destaining solution was replaced with another ~40 mL of destaining 
solution and rocked at room temperature overnight.  The destaining solution was removed and 
replaced with ~40 mL of distilled water and rocked at room temperature for 1 hour until the gel 
swelled to its original size and it was visualized with the Bio-Rad gel docking station. 
SyproRuby staining procedure 
This method was used to analyze more dilute fractions typically after size exclusion or 
reverse Ni-NTA purification.  40 mL of fixing solution was added into a clean, lightproof plastic 
container and the gel was added and rocked for 20 minutes at room temperature.  The fixing 
solution was replaced and washed for another 20 min.  The fixing solution was removed and 20 
mL of SyproRuby staining solution was added in the dark, and the gel was microwaved for 7 
seconds, it was rocked for 30 seconds, was microwaved another 7 seconds, rocked for 5 minutes 
and then was microwaved a third time for 7 seconds followed by rocking for 55 minutes at room 
temperature.  The SyproRuby was replaced with 40 mL of destaining solution and was rocked 
for 60 minutes at room temperature and then visualized on the Bio-Rad gel docking station. 
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α-Dicer Western blot 
After SDS-PAGE electrophoresis, the gel was washed in 40 mL of Towbin transfer 
buffer for 20 minutes.  A PDVF membrane was briefly wetted in MeOH followed by a 20 
minutes in 40 mL of Towbin transfer buffer.  Filter papers and Brillo pads were also equilibrated 
with Towbin transfer buffer.  The transfer cassette assembly was assembled by adding each layer 
in order onto the black side of a Bio-Rad western cassette in this order: Brillo pad, filter paper, 
gel, PVDF membrane, filter paper and Brillo pad.  The transfer cassette was loaded into the 
transfer chamber with the black on black, and the chamber was filled with fresh Towbin transfer 
buffer and an ice pack.  The proteins were transferred from the gel to the PVDF membrane at 60 
V for 90 minutes.  The PVDF membrane was placed in 20 mL of blocking solution (5% milk in 
PBS) and was rocked overnight at 4 °C.  In the morning, 0.5 µL (1:40,000) of α-Dicer mouse 
monoclonal antibody from Abcam (13D-6) was added to the blocking solution and was rocked 
for 1 hour at room temperature.  The excess antibody was removed with 4 washes with 20 mL of 
TBS-Tween (30 seconds, 30 seconds, 10 minutes, 10 minutes).  20 mL of PBS was added to the 
membrane and 1 µL (1:20,000) of α-mouse secondary antibody conjugated to HRP was added 
and rocked for 1 hour at room temperature.  The secondary antibody was removed with 4 washes 
of TBS-Tween (30 seconds, 30 seconds, 10 minutes, 10 minutes).  The membrane was incubated 
with 12 mL of Bio-Rad Pico luminescent solution (1:1 mixture of peroxide and enhancer 
solution) for 5 min.  The membrane was enclosed between plastic sheets and three exposures 
onto X-ray film were taken (10 second, 30 seconds and 120 seconds) and the film was developed 
then digitized on the Bio-Rad gel docking station. 
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3.5 TEV protease expression and purification 
His6-TEV (S219V)-Arg expression 
A streak plate containing His6-TEV (S219V)-Arg protease was received from Doug 
Mitchell’s laboratory at the University of Illinois.  A culture was grown and the plasmid was 
isolated and transformed into Rosetta cells.  An overnight culture of these cells was grown and a 
portion was frozen in 50% glycerol at -80 °C for long-term storage.  This frozen stock was used 
to inoculate (6) 50 mL conical vials containing 20 mL of LB media with antibiotic (100 µg/mL 
Ampicillin, 37 µg/mL Chloramphenicol) and the cultures were grown overnight at 37 °C at 250 
rpm.  The overnight cultures were transferred to (6) 4 L Erlenmeyer flasks containing 2 L of LB 
with antibiotic (100 µg/mL Ampicillin, 37 µg/mL Chloramphenicol) and were grown at 37 °C 
and 250 RPM to an OD 600 of 0.6.  Expression was induced with 1 mM IPTG (477 mg) and the 
cells were harvested 3.5-4 hours post induction.  The cells were pelleted by centrifugation at 
5,000 g for 5 min at 8 °C.  The cell pellets were frozen at -20 °C for further use. 
Ni-NTA purification of His6-TEV (S219V)-Arg 
A pellet from a 2L expression of His6-TEV (S219V)-Arg was resuspended in 20 mL of 
lysis buffer (50 mM Sodium Phosphate, dibasic (pH 8.0), 100 mM NaCl, 25 mM imidazole, 10% 
glycerol).  The cells were lysed via sonication on ice and 500 µL of polyethyleneimine was 
added to precipitate the DNA.  The lysate was centrifuged at 35,000 g for 30 min at 4 °C to 
removed cellular debris.  The supernatant was transferred into a 50 mL conical vial and 4 mL of 
Ni-NTA slurry was added, and the tube rocked for 1 hour at 4 °C.  The mixture was added to a 
column and the resin was allowed to pack by gravity flow.  The column was washed twice with 
15 mL of pre-chilled lysis buffer.  TEV protease was eluted with 7.5 mL of pre-chilled elution 
buffer (50 mM Sodium Phosphate, dibasic (pH 8.0), 100 mM NaCl, 200 mM imidazole, 10% 
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glycerol).  DTT and EDTA were added to the elution (final concentration of 1 mM each) to 
stabilize TEV protease.   
Size exclusion purification of His6-TEV (S219V)-Arg 
The elution was passed through a 0.2 µm syringe filter (it took 3) and was concentrated to 
2 mL using an Amicon centrifuge tube (MWCO:10,000) at 3,220 g at 4 °C.  A 16-60 S-75 gel 
filtration column was pre-equilibrated with 2 column volumes (240 mL) of gel filtration buffer 
(25 mM sodium phosphate, dibasic (pH 8.0), 200 mM NaCl, 2 mM EDTA, 10 mM DTT, 10% 
glycerol) at 4 °C.  The concentrated His6-TEV (S219V)-Arg was added via syringe into a 2 mL 
load loop on an AKTA-FPLC.  The protein was passed through the S-75 column with 1.5 CV 
(180 mL) of gel filtration buffer at a flow rate of 0.6 mL/min.  Fractions were collected every 5 
mL or every 3 mL where absorbance was above 5 mAu.  Fractions were analyzed by SDS-PAGE 
to determine which fractions contained His6-TEV (S219V)-Arg.  Void Volume – 45 mL, TEV 
protease elution volume – 62.5-75 mL (Kav: 0.30), Included Volume – 120 mL.  Fractions 
containing pure His6-TEV (S219V)-Arg were concentrated to 1 mg/mL and were flash frozen in 
liquid nitrogen and stored at -80 °C. A 2L expression typically yields 8 mg of pure protein. 
3.6 Design, cloning, expression and purification of TRBP peptide library 
Primer design 
A series of 10 overlapping 30 amino acid peptides and a full 68 amino acid peptide were 
deigned to map the region of TRBP that is critical for binding to Dicer.  Primers were ordered 
from IDT to generate these overlapping peptides 
299-366 
Forward Primer: CATGTAGGATCCAGTGAGCTCTCTGAGGAGCA 
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Reverse Primer: TAGCATCTCGAGTCACTTGCTGCCTGCCATGA 
299-328 
Forward Primer: CATGTAGGATCCAGTGAGCTCTCTGAGGAGCA 
Reverse Primer: TAGCATCTCGAGTCATTCCACCAGGCACTGGC 
304-333 
Forward Primer: CATGTAGGATCCGAGCAGGCCTTTCACGTCAG 
Reverse Primer: TAGCATCTCGAGTCACGGCTGGGTGGACAGTT 
309-338 
Forward Primer: CATGTAGGATCCGTCAGCTACCTGGATATTGA 
Reverse Primer: TAGCATCTCGAGTCAATGACACACAGTGGCCG 
314-343 
Forward Primer: CATGTAGGATCCATTGAGGAGCTGAGCCTGAG 
Reverse Primer: TAGCATCTCGAGTCAGGTGGTTGCAGAGCCAT 
319-348 
Forward Primer: CATGTAGGATCCCTGAGTGGACTCTGCCAGTG 
Reverse Primer: TAGCATCTCGAGTCAACGGGCTGCCTCCCTGG 
324-353 
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Forward Primer: CATGTAGGATCCCAGTGCCTGGTGGAACTGTC 
Reverse Primer: TAGCATCTCGAGTCAGCGGGCAGCCTCACCA 
329-358 
Forward Primer: CATGTAGGATCCCTGTCCACCCAGCCGGCCAC 
Reverse Primer: TAGCATCTCGAGTCAGTACTGCAGGGCACGG 
334-363 
Forward Primer: CATGTAGGATCCGCCACTGTGTGTCATGGCTC 
Reverse Primer: TAGCATCTCGAGTCATGCCATGATCTTGAGGT 
339-366 
Forward Primer: CATGTAGGATCCGGCTCTGCAACCACCAGGGA 
Reverse Primer: TAGCATCTCGAGTCACTTGCTGCCTGCCATGA 
PCR amplification of TRBP inserts 
Each primer was diluted to 100 µM by addition of 10 mM Tris (pH 8.0).  PCR was 
performed by mixing the following in a PCR tube: 5 µL 10x Taq polymerase reaction buffer, 12 
µL 8 mM dNTP mix, 1.5 µL 50 mM MgCl2, 1 µL TRBP pFastBac, 41.1 µL MilliQ H2O, 0.4 µL 
Forward primer, 0.4 µL Reverse primer, 0.5 µL Taq DNA polymerase (5 U/ µL).  The inserts 
were then amplified on a thermocycler with the following conditions: 
1) 94 °C – 5 minutes 
2) 94 °C – 30 seconds 
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3) 58 °C – 60 seconds 
4) 72 °C – 90 seconds 
5) Repeat steps 2-4 30 times 
6) 72 °C – 10 minutes 
7) 4 °C – Forever 
The PCR products were then loaded into a 1.75% agarose gel and run for 45 minutes at 
120 V.  The inserts were gel extracted using Qiagen’s gel extraction kit.   
pET28b+-MBP isolation 
E. coli containing pET28b+-MBP plasmid was obtained from Doug Mitchell at the 
University of Illinois.  A 12 mL culture was grown overnight in LB containing 50 µg/mL 
kanamycin at 37 °C and shaking at 250 rpm.  The cells were centrifuged at 3,220 g for 5 minutes 
and 500 µL of buffer P1 was added to the pellet.  The resuspended cells were transferred to a 1.5 
mL Eppendorf tube and 450 µL of buffer P2 was added and the tube was inverted 10 times.  650 
µL of buffer N3 was added and the tube was inverted 20 times.  The cellular debris was pelleted 
by centrifugation at 16,100 g for 10 minutes and the supernatant was transferred 750 µL at a time 
into a spin column and centrifuged at 16,100 g for 1 min after each addition.  The spin column 
was washed with 500 µL of buffer PB followed by a 1 minute spin.  The column was then further 
washed with 750 µL of buffer PE and followed by two 1-minute spins to completely remove 
residual buffer.  The DNA was eluted with the addition of 40 µL of 10 mM Tris (pH 8.0) and a 
1-minute spin into a new 1.5 mL eppendorf tube.  The DNA was quantified by UV absorbance at 
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260 nM.  Since pET28b+-MBP is a low copy number plasmid, this procedure typically yielded 
50-60 ng/µL of high quality plasmid DNA. 
Restriction digestion of TRBP inserts and pET28b+-MBP vector 
Both the vector and the inserts were sequentially digested using BamHI and XhoI 
restriction endonucleases.  5 µL of NEBuffer 2 and 1 µL of BamHI were added to 46 µL of 
pET28b+-MBP (55 ng/µL) or TRBP insert (15 ng/µL) and incubated for 2 hours at 37 °C.  After 
the incubation, using Qiagen’s PCR purification spin columns the DNA was purified and 
subsequently quantified by absorbance at 260 nm.  Both the vector and inserts were further 
digested by adding 5 µL of NEBuffer 2 and 1 µL of XhoI and incubating at 37 °C for 2 hours.  1 
µL of CIP alkaline phosphatase was added to the vector and incubated an additional hour.  The 
pET28b+-MBP vector was electrophoresed in a 1% agarose gel and gel extracted and purified, 
while the inserts were electrophoresed in a 1.75% gel and gel extracted and purified.  The final 
yields of double digested DNA were 20 ng/µL pET28b+-MBP and 10-15 ng/µL of each TRBP 
insert. 
Ligation and transformation of pET28b+-MBP and TRBP inserts 
The insert and vector were ligated using NEB’s quick ligation kit.  1 µL of pET28b+-
MBP vector, 0.5 µL insert, 8.5 µL MilliQ H2O, 10 µL 2x ligation buffer, and 1 µL T4 DNA 
ligase were combined in an eppendorf tube and incubated at room temperature for 5 minutes.  3 
µL of the ligation reaction was added to NEB turbocompetent cells and incubated on ice for 30 
minutes.   The cells were heat shocked at 42 °C for exactly 30 seconds and returned to the ice for 
a 5 minute incubation.  950 µL of SOC media was added and the cells were incubated for 1 hour 
at 37 °C with shaking at 250 rpm.  The cells were centrifuged at 4,000 g for 5 minutes and the 
supernatant was poured off and the cells were resuspended in the drop of remaining media.  The 
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resuspended cells were plated onto LB/agar plates containing 50 µg/mL kanamycin and 
incubated overnight at 37 °C. 
Sequencing plasmids 
Three colonies from each plate were selected and the correct ligation was verified by 
sequencing.  Briefly, 12 mL of LB media containing 50 µg/mL kanamycin was inoculated with a 
single colony and grown overnight at 37 °C with shaking at 250 rpm.  The plasmid DNA was 
isolated following the same procedure to isolate pET28b+-MBP plasmid.  Typically, the DNA 
concentration was 50-60 ng/µL with an Abs 260/280 of 1.7-1.9.  The DNA was submitted to the 
University of Illinois core sequencing facility and sequenced via Sanger sequencing using the T7 
terminator primer.  Due to the His6 sequence at the beginning of the read, the WORKS procedure 
was used and the sequence trace was manually inspected and edited. 
Transformation of plasmids containing fusion proteins into Rosetta 
2 µL of pET28b+-MBP plasmid containing the TRBP peptide insert was added to 60 µL 
of chemically competent Rosetta cells and incubated on ice for 20 minutes.  The cells were heat 
shocked at 42 °C for 30 seconds and then immediately returned to ice for 5 minutes.  950 µL of 
SOC media was added and the cells were incubated at 37 °C for 1 hour with shaking at 250 rpm.  
100 µL of cells were plated onto LB/agar plates containing 50 µg/mL kanamycin and 37 µg/mL 
chloramphenicol and incubated overnight at 37 °C.  A colony was selected for each of the 11 
constructs and 2 mL of LB containing 50 µg/mL kanamycin and 37 µg/mL chloramphenicol was 
inoculated with a single colony and grown overnight at 37 °C with shaking at 250 rpm.  1 mL of 
the overnight culture was mixed with 1 mL of glycerol and was flash frozen in liquid nitrogen in 
a cryogenic tube and stored at -80 °C for further use. 
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Expression of MBP-TRBP(peptides) fusion protein 
20 mL of LB containing 50 µg/mL kanamycin and 37 µg/mL chloramphenicol was 
inoculated with a frozen stock of Rosetta cells containing the gene for the fusion protein and 
grown overnight at 37 °C and shaking at 250 rpm.  The next day, 2 L of LB media containing 
antibiotics was inoculated with the 20 mL overnight culture and grown to an OD 600 of 0.6-0.7 
and expression was induced with 1 mM IPTG.  After induction the cells continued to grow for 
another 3.5-4 hours and the cells were pelleted by centrifugation at 5,000 g and the cell pellet 
was stored at -20 °C for further use. 
Ni-NTA purification of fusion protein 
A pellet from a 2L expression of fusion protein was resuspended to 20 mL of binding 
buffer buffer (50 mM Sodium Phosphate, dibasic (pH 8.0), 300 mM NaCl, 10 mM imidazole).  
The cells were lysed via sonication on ice and the lysate was centrifuged at 35,000 g for 30 min 
at 4 °C to removed cellular debris.  The supernatant was transferred into a 50 mL conical vial 
and 2 mL of Ni-NTA slurry was added, and the tube rocked for 1 hour at 4 °C.  The mixture was 
added to a column and the resin was allowed to pack by gravity flow.  The column was washed 
with 20 mL of pre-chilled binding buffer and subsequently washed with 20 mL of wash buffer 
(50 mM Sodium Phosphate, dibasic (pH 8.0), 300 mM NaCl, 20 mM imidazole).  The fusion 
protein was eluted with 10 mL of pre-chilled elution buffer (50 mM Sodium Phosphate, dibasic 
(pH 8.0), 300 mM NaCl, 500 mM imidazole). 
Concentration, dialysis, and TEV cleavage of fusion protein 
Since the peptide was small and not suitable for concentration or dialysis, these steps 
were performed first to concentrate the fusion protein and exchange the buffer into a low 
imidazole buffer before TEV cleavage.  The 10 mL of 2 mg/mL fusion protein was added to an 
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Amicon concentrating tube (MWCO: 3500) and centrifuged at 4 °C until the volume was 2 mL 
and the concentration was 10 mg/mL.  This concentrated fusion protein was loaded into a 
dialysis cassette and dialysed overnight against 1 L of 4 °C wash buffer (50 mM sodium 
phosphate, dibasic (pH 8.0), 300 mM NaCl, 300 mM imidazole (pH 8.0), 1 mM TCEP[tris(2-
carboxyethyl)phosphine], 5% glycerol).  The dialysed protein was transferred to a 2 mL 
Eppendorf tube and 100 µL of 1 mg/mL TEV protease was added and incubated overnight at 4 
°C. 
Reverse Ni-NTA purification of TRBP peptide 
After overnight cleavage of the TRBP peptide from MBP, the peptide was isolated by 
reverse NI-NTA chromatography.  1 mL of Ni-NTA slurry was added to a 15 mL conical vial 
and the cleavage mixture was also added.  The tube was rocked for 1 hour at 4 °C.  Next, the 
mixture was poured over a column and the flow-through was collected by gravity flow.  The 
column was washed with 2 mL of wash buffer (50 mM Sodium Phosphate, dibasic (pH 8.0), 300 
mM NaCl, 20 mM imidazole) and the flow through was collected.  The column was 
subsequently washed with 15 mL of wash buffer and then the contaminating proteins were 
removed from the column by washing with 6 mL of elution buffer (50 mM Sodium Phosphate, 
dibasic (pH 8.0), 300 mM NaCl, 500 mM imidazole).  All fractions were analyzed by SDS-
PAGE and MALDI mass spectrometery. 
HPLC purification of TRBP peptide 
Fractions containing peptides (FT and W1) were injected onto a C-18 prep grade HPLC 
column that was pre-equilibrated with 5% acetonitrile in water with 0.1% TFA.  The 
concentration of acetonitrile was increased to 95% over 40 minutes with a flow rate of 10 
mL/min and the UV was measured at 254 nm and 280 nm.  Some of the peptides contain a 
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tyrosine and absorb at 280 nm, but others have no aromatic amino acids and must be monitored 
at 254 nm.  10 mL fractions were collected every minute and peak fractions, according to the UV 
trace, were submitted to MALDI-mass spectrometry to determine which fractions contain the 
purified and desalted peptide.   
3.7 Malachite Green assay 
Designing and ordering DNA olionucleotides 
 Five DNA oligonucleotides were ordered from Integrated DNA Technologies (IDT).  A 
T7 primer, 3 Malachite Green aptamers and 1 SRB aptamer.   
T7-primer 5-AGCTTAATACGACTCACTATAGGA-3 
 
Malachite Green aptamer (0) 5’-
AAGGAGGTAGTAGGTTGTGGATCCATTCGTTACCTGGCTCTCGCCAGTCGGGATCCA
CAACCTACTACCTCCTATAGTGAGTCGTATTAAGCT -3’ 
 
Malachite Green aptamer (-1) 5- 
AAGGAGGTAGTAGGTTGGGATCCATTCGTTACCTGGCTCTCGCCAGTCGGGATCCCA
ACCTACTACCTCCTATAGTGAGTCGTATTAAGCT -3 
 
Malachite Green aptamer (-2) 5- 
AAGGAGGTAGTAGGTTGGATCCATTCGTTACCTGGCTCTCGCCAGTCGGGATCCAAC
CTACTACCTCCTATAGTGAGTCGTATTAAGCT -3 
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SRB aptamer 5- 
AAGGAGGTAGTAGGTTGGGAACCTGAGGCGGTTAACCTTGCGCCTCTCCATCATCGC
CGAAGCGAGGTTCCCAACCTACTACCTCCTATAGTGAGTCGTATTAAGCT -3 
The Malachite Green aptamers each contain the original Malachite Green aptamer and 
additional bases from the stem of the pre-Let-7 miRNA.  All of the studies performed used the 
Malachite Green aptamer (0), the other three aptamers: Malachite Green aptamer (-1), Malachite 
Green aptamer (-2) and the SRB aptamer were all ordered but never used.  The imputus for 
ordering the other aptamers was to test if different cleavage sites or aptamers would be amenable 
to a continuous fluorescence based assay.  
T7 in vitro transcription assay 
3.0 nmol of Malachite Green aptamer (0) was dissolved in 300 µL of 10 mM Tris (pH 
8.0) and 30.4 nmol of T7 primer were dissolved in 304 µL of 10 mM Tris (pH 8.0).  Next, 178 
µL of annealing buffer (50 mM NaCl, 100 mM HEPES (pH7.4)), 20 µL of Malachite Green 
aptamer (0) (200 pmol) and 2 µL of T7 primer (200 pmol) were mixed.  The strands were 
annealed by increasing the temperature to 95 °C for 5 minutes and slowly cooling to 25 °C over 
10 minutes.  30 µL of the annealed DNA was added to 122.5 µL MilliQ water, 12.5 µL rNTPs 
(80 mM each), 10 µL RNAse out (400 units), 100 µL DTT (Invitrogen), 200 µL transcription 
buffer (Invitrogen), 25 µL T7 RNA polymerase (500 units) (Invitrogen).  The mixture was 
incubated overnight at 37 °C.  Next, The RNA and the excess rNTPs were precipitated by adding 
167 µL of 7.5 M Ammonium Acetate and 1 mL of 100% ethanol and incubating at -80 °C for 1 
hour on dry ice and acetone.  The RNA was pelleted by centrifugation at 22,000 g on a tabletop 
centrifuge for 5 minutes.  The supernatant was replaced with 1 mL of 70% ethanol and the pellet 
was resuspended and centrifuged.  After centrifugation the supernatant was discarded and the 
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pellet was briefly air-dried.  Next, the RNA pellet was resuspended in 40 µL of MilliQ water and 
then 144 µL of formamide and 72 µL of glycerol were added as a loading buffer.  The RNA was 
heated to 65 °C for 15 minutes and then cooled to 4 °C.  Next, 1 L of 1X TBE was prepared by 
mixing 1 part 10X TBE buffer (890 mM Tris Base, 890 mM Boric Acid, 20 mM EDTA – do not 
pH, pH should already be at 8.3, filter-sterilized) with 9 parts MilliQ water.  The 1X TBE was 
placed in a Bio-Rad electrophoresis chamber with a TGX-Tris-Glycine 10 well 12% gel and the 
gel was pre-run at 60 V for 20 minutes.  30 µL of RNA were added to each lane until all of the 
RNA was loaded and the RNA was electrophoresed at 60 V for 2 hours.  After electrophoresis, 
the gel was removed and wrapped in plastic wrap.  The gel, in plastic wrap, was placed over a 
UV active thin-layer chromatography (TLC) plate and illuminated with 254 nm UV light.  The 
transcribed RNA and the free rNTPs absorb the UV light and cast a shadow on the TLC plate.  
Using a clean razor blade, the polymerized RNA aptamer is excised.  The gel is placed in 
dissociation buffer and rocked overnight.  The dissociation buffer is collected in the morning, 
which contains the RNA, and the RNA was precipitated following the same procedure as above.  
The RNA aptamer was resuspended in MilliQ water and quantified by measuring the absorbance 
at 260 and 280 nm. 
Refolding of Malachite Green aptamer 
The Malachite Green aptamer was diluted into binding buffer (100 mM KCl, 5 mM 
MgCl2, 10 mM HEPES (pH 7.4)) to 10 µM.  The aptamer was heated to 65 °C and slowly 
cooled to 25 °C to correctly fold the aptamer. 
Testing Malachite Green binding to the aptamer 
100 µM Malachite Green was freshly prepared by dissolving Malachite Green (solid) in 
binding buffer and making serial dilutions until the concentration was 100 µM.  10 µL of 100 µM 
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Malachite Green was added to 90 µL of binding buffer or 80 µL of binding buffer and 10 µL of 
10 µM folded Malachite Green aptamer (1 µM final concentration) in a 96 well plate.  Each well 
was excited with 595 nm light and the fluorescence emission spectrum was measured between 
640 and 700 nm.  Note: a fresh stock of Malachite Green was prepared for every assay due to the 
rapid spectral decay of Malachite Green. 
Dicing experiment with Malachite Green aptamer 
10 µL of refolded Malachite Green aptamer (10 µM) was added to 70 µL of Dicer 
cleavage buffer (100 mM KCl, 3 mM MgCl2, 40 mM HEPES (pH 7.5)) in a 96 well fluorescent 
plate.  0, 1, 2.5, 5, or 10 µL of Ni-NTA purified Dicer was added to each well and SF9 elution 
buffer was added to make the final volume 90 µL.  After a 1 hour incubation at 37 °C, 10 µL of 
fresh 100 µM Malachite Green was added to each well.  Each well was excited with 595 nm light 
and the emission was measured at 655 nm.  Note: Dicer stability is improved in the presence of 
reducing agents such as DTT or BME; however, Malachite Green reacts with reducing agents 
and these reagents are incompatible in this assay. 
3.8 Cy5/IowaBlk assay 
Selection and ordering of RNA probes 
The methods in this section are adapted from DiNitto et al.76  The most effective dsRNA 
substrate from their paper was selected to be used for further testing as a probe for detecting 
enhancers of Dicer activity.  These two RNA oligonucleotides that contain a Cy5 label or an 
IowaBlk quencher were ordered from IDT. 
Cy5 RNA 27 bases 5’- 
/5Cy5/rCrArUrGrArCrUrUrUrGrGrCrArArArGrUrGrArGrGrArUrGrUrArG-3’ 
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IowaBlk RNA 25 bases 5’- 
rArCrArUrCrCrUrCrArCrUrUrUrGrCrCrArArArGrUrCrATG/3IAbRQSp/ -3’ 
These two custom RNA oligonucleotides were purified by RNAse free HPLC 
purification and they were resuspended to 20 µM in filter-sterilized reaction buffer (200 mM Tris 
(pH 9.0), 150 mM NaCl, 20 mM MgCl2).   
Measuring fluorescence of annealed RNA and Cy5 alone 
10 µL of Cy5 RNA was mixed with 11 µL of IowaBlk RNA and the two were annealed 
by heating to 95 °C and slowly cooling to 25 °C over 10 minutes; also 10 µL of Cy5 RNA 
followed the same annealing procedure, but without the complimentary IowaBlk RNA strand.  In 
a black clear-bottom 384 well plate, 1 µL of Cy5 RNA or 2.1 µL of annealed RNA (contains 
only 1 µL of Cy5 RNA) were added to enough reaction buffer to make the final volume 50 µL 
(The reaction buffer and the plate were pre-equilibrated to 30 °C before addition of the RNA).  
35 µL of mineral oil was added to each well and the plate was centrifuged at 4000 g for 1 minute 
to eliminate any air bubbles and to help separate the oil from buffer.  The emission was read at 
673 nm with an excitation wavelength of 645 nm in a bottom read fluorimeter. 
Dicing assay with Cy5/IowaBlk probe 
1.1 equivalents of IowaBlk RNA are used in annealing reaction with 1 equivalent of Cy5 
RNA to assure that all of the Cy5 fluorescence is quenched.  After performing the annealing 
procedure on both the annealed RNA and the Cy5 alone, the assays were set up in 384 well black 
clear bottom plates.  Each well contains a total volume of 50 µL. 
Reactions included: reaction buffer (enough to make total volume 50 µL), A combination 
of Dicer or elution buffer (10 µL), annealed RNA (2.1 µL).  Sometimes the reactions included 
detergents, or other proteins like TRBP or BSA; each variable was accounted for and the 
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appropriate buffer was selected to keep the total volume at 50 µL in each case.  In some cases 35 
µL of mineral oil was added to prevent evaporation, this does not factor into the 50 µL total 
volume.  When detergents were used, mineral oil was not an option since the detergents form an 
emulsion between the oil and buffer layers. 
The buffer, Dicer and the plate were pre-warmed to 30 °C and then the RNA was added 
(2.1 µL annealed RNA or 1 µL Cy5 RNA alone).  If detergents were not used, the mineral oil 
was added.  At this point, the plate was centrifuged at 4000 g for 1 minute.  The fluorescence 
emission was measured over 4-12 hours every 30 seconds at 673 nm with an excitation 
wavelength of 645 nm. 
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